WO1999051241A1 - Calcilytic compounds and method of use - Google Patents

Calcilytic compounds and method of use Download PDF

Info

Publication number
WO1999051241A1
WO1999051241A1 PCT/US1999/007760 US9907760W WO9951241A1 WO 1999051241 A1 WO1999051241 A1 WO 1999051241A1 US 9907760 W US9907760 W US 9907760W WO 9951241 A1 WO9951241 A1 WO 9951241A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
alkyl
chloro
hydroxy
dimethyl
Prior art date
Application number
PCT/US1999/007760
Other languages
French (fr)
Inventor
Pradip Kumar Bhatnagar
James Francis Callahan
Eric G. Del Mar
Maria Amparo Lago
Original Assignee
Smithkline Beecham Corporation
Nps Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corporation, Nps Pharmaceuticals, Inc. filed Critical Smithkline Beecham Corporation
Priority to CA002327188A priority Critical patent/CA2327188A1/en
Priority to AU35513/99A priority patent/AU3551399A/en
Priority to JP2000542012A priority patent/JP2002510636A/en
Priority to EP99917374A priority patent/EP1069901A4/en
Publication of WO1999051241A1 publication Critical patent/WO1999051241A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/54—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals

Definitions

  • the present invention relates to novel calciiytic compounds, pharmaceutical compositions containing these compounds and their use as calcium receptor antagonists.
  • extracellular Ca ⁇ + In mammals, extracellular Ca ⁇ + is under rigid homeostatic control and regulates various processes such as blood clotting, nerve and muscle excitability, and proper bone formation.
  • Extracellular Ca ⁇ + inhibits the secretion of parathyroid hormone ("PTH") from parathyroid cells, inhibits bone resorption by osteoclasts, and stimulates secretion of calcitonin from C-cells.
  • PTH parathyroid hormone
  • Calcium receptor proteins enable certain specialized cells to respond to changes in extracellular Ca ⁇ + concentration.
  • PTH is the principal endocrine factor regulating Ca ⁇ + homeostasis in the blood and extracellular fluids.
  • PTH by acting on bone and kidney cells, increases the level of Ca ⁇ + in the blood. This increase in extracellular Ca ⁇ + then acts as a negative feedback signal, depressing PTH secretion.
  • Extracellular Ca ⁇ + acts directly on parathyroid cells to regulate PTH secretion. The existence of a parathyroid cell surface protein which detects
  • this protein acts as a calcium receptor
  • extracellular Ca2+ plays a role in parafollicular (C-cells) and parathyroid cells. See Nemeth, Cell Calcium 11:323, 1990.
  • the role of extracellular Ca ⁇ + on bone osteoclasts has also been studied. See Zaidi, Bioscience Reports 10:493, 1990.
  • Calcilytics are compounds able to inhibit calcium receptor activity, thereby causing a decrease in one or more calcium receptor activities evoked by extracellular Ca + .
  • Calcilytics are useful as lead molecules in the discovery, development, design, modification and/or construction of useful calcium modulators which are active at Ca + receptors.
  • Such calcilytics are useful in the treatment of various disease states characterized by abnormal levels of one or more components, e.g., polypeptides such as hormones, enzymes or growth factors, the expression and/or secretion of which is regulated or affected by activity at one or more Ca + receptors.
  • Target diseases or disorders for calcilytic compounds include diseases involving abnormal bone and mineral homeostasis.
  • Abnormal calcium homeostasis is characterized by one or more of the following activities: an abnormal increase or decrease in serum calcium; an abnormal increase or decrease in urinary excretion of calcium; an abnormal increase or decrease in bone calcium levels (for example, as assessed by bone mineral density measurements); an abnormal absorption of dietary calcium; an abnormal increase or decrease in the production and/or release of messengers which affect serum calcium levels such as PTH and calcitonin; and an abnormal change in the response elicited by messengers which affect serum calcium levels.
  • calcium receptor antagonists offer a unique approach towards the pharmacotherapy of diseases associated with abnormal bone or mineral homeostasis, such as hypoparathyroidism, osteosarcoma, periodontal disease, fracture healing, osteoarthritis, rheumatoid arthritis, Paget's disease, humoral hypercalce ia associated with malignancy and fracture healing, and osteoporosis.
  • the present invention comprises novel calcium receptor antagonists represented by Formula (I) hereinbelow and their us in the treatment of a variety of diseases associated with abnormal bone or mineral homeostasis, including but not limited to hypoparathyroidism, osteosarcoma, periodontal disease, fracture healing, osteoarthritis, rheumatoid arthritis, Paget's disease, humoral hypercalcemia associated with malignancy and fracture healing, and osteoporosis.
  • diseases associated with abnormal bone or mineral homeostasis including but not limited to hypoparathyroidism, osteosarcoma, periodontal disease, fracture healing, osteoarthritis, rheumatoid arthritis, Paget's disease, humoral hypercalcemia associated with malignancy and fracture healing, and osteoporosis.
  • the present invention further provides a method for antagonizing calcium receptors in an animal, including humans, which comprises administering to an animal in need thereof an effective amount of a compound of Formula (I), indicated hereinbelow.
  • the present invention further provides a method for increasing serum parathyroid levels in an animal, including humans, which comprises administering to an animal in need thereof an effective amount of a compound of Formula (I), indicated hereinbelow.
  • Y is a covalent bond, alkylene or alkenylene of up to 4 carbon atoms, unsubstituted or substituted by C 1.4 alkyl or O;
  • Y2 is methylene, unsubstituted or substituted by C 1.4 alkyl or haloalkyl
  • Y3 is covalent bond or O, S, N-R ⁇ or C1.4 alkylene-O, C j _4 alkylene-S, C1.4 alkylene-N-R ⁇ V ;
  • R ⁇ is selected from the group consisting of H, Cj_4 alkyl, C3.6 cycloalkyl;
  • R3 and R4 are, independently, methyl or ethyl, or, together, form cyclopropyl
  • R5 is heteroaryl or fused heteroaryl; wherein the hetero-ring contains N, O or S, and is aromatic, dihydro or tetrahydro, unsubstituted or substituted with any substituents being selected from the group consisting of OH, OCH3, CH(CH3)2, halogen, C ⁇ _4 alkyl, Cj_4 alkoxy, C 3 . 6 cycloalkyl, OS0 2 R IV , CN, N0 2 , OCF3,
  • n is an integer from 0 to 3;
  • G is a covalent bond, CHRg or C-Rg ,wherein Rg is H, OH or O (forming a ketone); R 7 is H, OH, or 0-C ⁇ _4 alkyl;
  • Rg is H or C ⁇ _4 alkyl; or R7 and Rg together form a ketone;
  • a and B are, independently, selected from the group consisting of a bond, CH2,
  • X is selected from sub formulas (la) to (Ie) hereinbelow:
  • W is selected from the group consisting of Ri , SO2R1, C(0)R ⁇ , SO2NR1R1 , C(0)NR ⁇ R ⁇ ', C(0)OR ⁇ , SO3R1', wherein R ⁇ and Ri 'are independently selected from the group consisting of hydrogen, Cj_4 alkyl, C3.6 cycloalkyl, C2.5 alkenyl, C2.5 alkynyl, heterocycloalkyl, aryl and aryl C1.4 alkyl; or R ⁇ and Ri together form a 3 to 7 membered optionally substituted heterocyclic ring; wherein any substituents are selected from the group consisting of CN, aryl, CO2R, CO2NHR, OH, OR, NH2, halo, CF3, OCF3 and N0 2 ; wherein R represents C ⁇ _4 alkyl, or C3.
  • Xi is selected from the group consisting of CN, NO2, Cl, F, Br, I, H, R ⁇ OR', CF3, OCF3 and OSO2R', wherein R' represents C ⁇ _4 alkyl, or C3.6 cycloalkyl;
  • X2 , X3 and X4 are, independently, selected from the group consisting of CN, N0 2 , Cl, F, Br, I, H, R", OR", CF 3 , OCF3 and OS0 2 R", provided that either X!
  • X3 is H, wherein R" is C ⁇ 4 alkyl or haloalkyl; or X j and X2 together form an aryl or heteroaryl ring, substituted or unsubstituted; wherein the heteroatom is selected from N, S and O; and any substituents are selected from the group consisting of halo, C ⁇ _4 alkyl, OCF 3 , CF3, OMe, CN, OS0 2 R' and N0 2 ; or X3 and X4 independently represent C(0)R ⁇ ; and
  • R2 is selected from the group consisting of hydrogen, Cj_4 alkyl, C3.6 cycloalkyl, C2-5 alkenyl, C2-5 alkynyl, heterocycloalkyl aryl and aryl-Ci.4 alkyl;
  • X j " is selected from the group consisting of CN, NO2, Cl, F, Br, I, H, R, OR, CF3, OCF3 and OSO2R, wherein R represents C ⁇ alkyl, or C3.6 cycloalkyl;
  • X2", X3" and X4" are, independently, selected from the group consisting of CN, N0 2 , Cl, F, Br, I, H, R ⁇ OR', CF3, OCF3 and OS0 2 R ⁇ provided that either X"!
  • X"3 is H, wherein R' is C 1.4 alkyl or haloalkyl; or Xi ' and X2" together form an aryl or heteroaryl ring, substituted or unsubstituted; wherein the heteroatom is selected from N, S and O and any substituents are selected from the group consisting of halo, Cj_4 alkyl, OCF3, CF3, OMe, CN, OS0 2 -C ⁇ _ 4 alkyl, OSO2- C3-6 cycloalkyl and NO2; or X3" and X4" independently represent C(0)R ⁇ ; and
  • R j " and R2" are, independently, selected from the group consisting of hydrogen, Cj_4 alkyl, C3.6 cycloalkyl, C2.5 alkenyl, C2.5 alkynyl, heterocycloalkyl and aryl; or Rj" and R2" together form a 3 to 7 membered optionally substituted heterocyclic ring; wherein any substituents are selected from the group consisting of CN, aryl, C0 2 R", C0 2 NHR", OH, OR", NH 2 , halo, CF3, OCF3 and N0 2 ; wherein R" represents ⁇ _ ⁇ alkyl, or C3.6 cycloalkyl; X m is selected from the group consisting of CN, NO2, Cl, F, Br, I, H, R, OR, CF3, OCF3 and OSO2R, wherein R represents C ⁇ _4 alkyl, or C3.6 cycloalkyl;
  • X2"', X3"', and X4"' are, independently, selected from the group consisting of CN, N0 2 , Cl, F, Br, I, H, R', OR', CF3, OCF3 and OS0 2 R', provided that either m ⁇ or X"'3 is H, wherein R' is Cj_4 alkyl or haloalkyl; or Xi '" and X2'" together form an aryl or heteroaryl ring, substituted or unsubstituted; wherein the heteroatom is selected from N, S and O and the substituents are selected from the group consisting of halo, C1.4 alkyl, OCF3, CF3,
  • Rj'" and R2" are, independently, selected from the group consisting of hydrogen, C 4 alkyl, C3.6 cycloalkyl, C2.5 alkenyl, C2-5 alkynyl, heterocycloalkyl and aryl; or R ⁇ '"and R2"' together form a 3 to 7 membered optionally substituted heterocyclic ring; wherein the substituents are selected from the group consisting of CN, aryl, C0 2 R", C0 2 NHR", OH, OR", NH 2 , halo, CF 3 , OCF3 and N0 2 ; wherein
  • R" represents C ⁇ _4 alkyl, or C3.6 cycloalkyl
  • D is selected from the group consisting of H, CN, NO2, Cl, F, Br, I, R, OR, SR,
  • R represents C1.4 alkyl, C3.6 cycloalkyl, or C ⁇ _ 10 ar yl or heteroaryl wherein the heteroatom is selected from N, S and O and substituents are selected from the group consisting of halo, C1.4 alkyl, OCF3, CF3,
  • n is the integer 1 or 2; each E is independently C or N, provided that no more than two E moieties are N; further provided that when n is 2, each E is C; a and b are optionally present bonds;
  • Ri ⁇ is selected from the group consisting of (CH2) n C ⁇ 2R ⁇ (CH2) n C ⁇ 2H,
  • R2TM is selected from the group consisting of hydrogen, CN, NO2 Cl, F, Br, I, H,
  • R represents C ⁇ _4 alkyl, or C3.6 cycloalkyl.
  • Y is selected from the group consisting of C, CH, O, N and S; provided that when
  • Y is S, R ⁇ ,v is O or not present; further provided that when Y is O, R ⁇ 1V is not present;
  • X' is selected from the group consisting of CH2, NH, O and S.
  • R9 is selected from the group consisting of O-alkyl, 0-CH2-aryl, and O- aryl;
  • X ⁇ "" is selected from the group consisting of CN, NO2, Cl, F, Br, I, H, R, OR,
  • R represents C1.4 alkyl, or C3.6 cycloalkyl
  • X2'"', X3"", and X4"" are, independently, selected from the group consisting of CN,
  • X""3 is H, wherein R' is C1.4 alkyl or haloalkyl; or X 1 "" and X2"" together form an aryl or heteroaryl ring, substituted or unsubstituted; wherein the heteroatom is selected from N, S and O and the substituents are selected from the group consisting of halo, Ci .4 alkyl, OCF3, CF3,
  • the compounds of the present invention have a structure according to Formula (H):
  • R5 is heteroaryl or fused heteroaryl, wherein the hetero- ring contains N, O or S and is aromatic, dihydro or tetrahydro, unsubstituted or substituted with any substituents being selected from the group consisting of OCH3, halogen, C ⁇ 4 alkyl, , CN, N0 2 , OCF3, CF3, CH 2 CF 3 ; Rg is H; and
  • R5 is heteroaryl or fused heteroaryl, wherein the hetero-ring contains N, O or S and is aromatic, dihydro or tetrahydro, unsubstituted or substituted with any substituents being selected from the group consisting of OCH3, halogen, C ⁇ .4 alkyl, , CN, N0 2 , OCF3, CF 3 , CH 2 CF 3 ;
  • Rg is H; and
  • a and B are, independently, selected from the group consisting of a bond, CH2, 0, or A and B together form a bond.
  • X j is selected from the group consisting of CN, NO2, Cl, F, Br, I and H.
  • X2, X3 and X4 are, independently, selected from the group consisting of Cl, F, Br, I and H, provided X ⁇ and X3 is H.
  • R ⁇ , Rj'and R2 are, independently, selected from the group consisting of C1.4 alkyl, C3.6 cycloalkyl, heterocycloalkyl, aryl or arylalkyl.
  • R ⁇ , Rj'and R2 are, independently, H, alkyl, or aryl. More preferably, X ⁇ is selected from the group consisting of CN, NO2, Cl, F, Br, I and H. More preferably, X2, X3 and X4 are, independently, selected from the group consisting of Cl, F, Br, I and H provided X j and X3 is H. In sub-formula (la), more preferably still, R , Ri 'and R2 are, independently, C . ⁇ alkyl, or aryl. More preferably still, X ⁇ is CN, NO2, or Cl. More preferably still, X2 is Cl, F or H. More preferably still, X3 and X4 are H.
  • X ⁇ is CN, or NO2.
  • X 2 is Cl.
  • Xi " is selected from the group consisting of CN, NO2, Cl, F, Br, I and H.
  • X2", X3" and X4" are, independently, selected from the group consisting of Cl, F, Br, I and H.
  • R ⁇ " and R2" are, independently, selected from the group consisting of C 1.4 alkyl, C3.6 cycloalkyl, heterocycloalkyl or aryl; or Ri “ and R2" together form an optionally substituted 3-7 membered ring, optionally containing an additional heteroatom selected from O, S, and N.
  • Ri " and R2" are, independently, H, C1.4 alkyl, or aryl; or R ⁇ " and R2" together form an optionally substituted 4-7 membered ring, optionally containing a heteroatom selected from O, S, and N. More preferably, Xi " is selected from the group consisting of CN, NO2, Cl, F, Br, I and H. More preferably, X2" is selected from the group consisting of Cl, F, Br, I and H.
  • Ri 'and R2" are, independently, C ⁇ _4 alkyl, or aryl; or R ⁇ " and R2" together form a 4-7 membered ring as described hereinabove. More preferably still, X ⁇ " is CN, NO2, or Cl. More preferably still, X 2 " is Cl, F or H. In sub-formula (Ib), most preferably, R " and R2" together form a 4-7 membered ring as described hereinabove. Most preferably, X ⁇ " is CN, or N ⁇ 2- Most preferably, X2 "is Cl.
  • XiTM is selected from the group consisting of CN, NO2, Cl, F, Br, I and H.
  • X2'", X ⁇ and X4 m are, independently, selected from the group consisting of Cl, F, Br, I and H. provided either X ⁇ "Or X3 m is H.
  • R ⁇ m and R2"' are, independently, selected from the group consisting of Cj_4 alkyl, C3.6 cycloalkyl, heterocycloalkyl or aryl; or R ⁇ m and R2"' together form an optionally substituted 3-7 membered ring, optionally containing an additional heteroatom selected from O, S, and N.
  • R ⁇ m , and R2"' are, independently, H, C j _4 alkyl, or aryl; or Rj"' and R2"' together form an optionally substituted 4-7 membered ring, optionally containing a heteroatom selected from O, S, and N.
  • X ⁇ m is selected from the group consisting of CN, NO2, Cl, F, Br, I and H.
  • X ⁇ , X3TM and X4TM are, independently, selected from the group consisting of Cl, F, Br, I and H provided either X "' or X3"' is H.
  • R ⁇ "'and R2TM are, independently, C ⁇ _4 alkyl, or aryl; or R ⁇ '" and R2"' together form a 4-7 membered ring as described hereinabove.
  • XiTM is CN, NO2, or Cl.
  • X2 " is Cl or H.
  • X3'" and X 4 '" are H.
  • Ri '" and R2'" together form a 4-7 membered ring as described hereinabove.
  • X ⁇ m is CN or NO2.
  • X2 '" is Cl.
  • each D is selected from the group consisting of F, Br, Cl, I, R, OR, SR, and H.
  • R2* v is selected from the group consisting of hydrogen, CN, NO2 Cl, Br, F and I; In sub-formula (Id), more preferably, n is O. More preferably, each E is C.
  • X' is CH2, O, or NH. More preferably, Y is C or N. More preferably, Ri ⁇ v is CH2CO2R', SR', or O forming a ketone.
  • X' is CH2 or O. More preferably still, Ri 1V is CH 2 C0 2 R' or SR'. More preferably still, R 2 ' v is H, CN, or N0 2 .
  • X' is CH2.
  • Y is C.
  • R2 ⁇ v is CN or NO2.
  • R9 is selected from the group consisting of
  • Xi "" is selected from the group consisting of CN, NO2, Cl, F, Br, H, R, and
  • OSO2R wherein R represents ⁇ . 4 alkyl, or C3.6 cycloalkyl
  • X2"", X3"", and X4" are, independently, selected from the group consisting of CN, NO2, Cl, F, Br, H,and OS02R', provided that either X"" ⁇ or X""3 is H, wherein R' is C j _4 alkyl or haloalkyl; or Xj "" and X2"" together form an aryl or heteroaryl ring, substituted or unsubstituted; wherein the heteroatom is selected from N, S and O and the substituents are selected from the group consisting of halo, C ⁇ 4 alkyl, OCF3, CF3, OMe, CN, OS ⁇ 2-C!. 4 alkyl, OSO2-C3.6 cycloalkyl and N0 2 ; or X2"" and X4 "" independently represent C(0)Rj;
  • R9 is selected from the group consisting of 0-(CH2)n-aryl, and O- aryl;
  • Xi "" is selected from the group consisting of CN, NO2, and Cl X2"".
  • X3"". and X4"" are, independently, selected from the group consisting of Cl,
  • R9 is selected from the group consisting of 0-(CH2)n-aryl, and O- aryl; X 1 "" is CN or N ⁇ 2,
  • X 2 " " is Cl
  • X 3 "” and X 4 "" are, independently F, and H.
  • Preferred heteroaryls useful in the present invention include unsubstituted and substituted quinolines, isoquinolines, benzofurans, dihydrobenzofurans, benzothiophenes, dihydrobenzothiophenes and pyridines.
  • cycloalkyl refers to optionally substituted 3-7 membered carbocyclic rings wherein any substituents are selected from the group consisting of, F, Cl, Br, I, N(Rj)2, SRj and ORi, unless otherwise indicated.
  • heterocycloalkyl refers to optionally substituted 4, 5, 6 or 7 membered heterocyclic rings containing 1 to 2 heteroatoms selected from N, O, and S.
  • aryl refers to an optionally substituted aromatic group with at least one ring having a conjugated pi-electron system, containing up to two conjugated or fused ring systems.
  • Aryl includes carbocyclic aryl, and biaryl groups, all of which may be optionally substituted.
  • Preferred aryl include phenyl and naphthyl. More preferred aryl include phenyl.
  • Preferred substituents are selected from the group consisting of halo, Cj_4 alkyl, OCF3 CF3 OMe, CN, OS ⁇ 2 R nd N ⁇ 2 wherein R represents ⁇ alkyl or C3.6 cycloalkyl.
  • acyl refers to C1.4 alkylcarbonyl.
  • alkenyl refers to an optionally substituted hydrocarbon group containing at least one carbon-carbon double bond and containing upto 5 carbon atoms joined together.
  • the alkenyl hydrocarbon chain may be straight, branched or cyclic. Any substituents are selected from the group consisting of halo, C1..4 alkyl, OCF3 5 CF 3> OMe, CN, OSO2 R and N02, wherein R represents C ⁇ _4 alkyl or C3.6 cycloalkyl.
  • alkynyl refers to an optionally substituted hydrocarbon group containing at least one carbon-carbon triple bond between the carbon atoms and containing up to 5 carbon atoms joined together.
  • the alkynyl hydrocarbon group may be straight-chained, branched or cyclic. Any substituents are selected from the group consisting of halo, C ⁇ 4 alkyl, OCF3, CF3, OMe, CN, OSO2 R and NO2, wherein R represents C1.4 alkyl or C3.6 cycloalkyl.
  • the compounds of the present invention may contain one or more asymmetric carbon atoms and may exist in racemic and optically active forms. All of these compounds and diastereomers are contemplated to be within the scope of the present invention.
  • Preferred compounds of the present invention are selected from the group consisting of: (R)-N-[2-Hydroxy-3-(3-chloro-2-cyanophenoxy)propyl]-l,l-dimethyl-2-(2,3- dihydrobenzo[b]furan-5yl)ethylamine;
  • 2-ynylamine and pharmaceutically acceptable salts and complexes thereof.
  • Preferred salts include hydrochloride and dihydrochloride.
  • More preferred compounds useful in the present invention include: (R)-N-[2-Hydroxy-3-(3-chloro-2-cyanophenoxy)propyl]-l,l-dimethyl-2-(2,3- dihydrobenzo[b]furan-5yl)ethylamine;
  • Pharmaceutically acceptable salts are non-toxic salts in the amounts and concentrations at which they are administered.
  • Pharmaceutically acceptable salts include acid addition salts such as those containing sulfate, hydrochloride, fumarate, maleate, phosphate, sulfamate, acetate, citrate, lactate, tartrate, methanesulfonate, ethanesulfonate, benzenesulfonate, p- toluenesulfonate, cyclohexylsulfamate and quinate.
  • a preferred salt is a hydrochloride.
  • Pharmaceutically acceptable salts can be obtained from acids such as hydrochloric acid, maleic acid, sulfuric acid, phosphoric acid, sulfamic acid, acetic acid, citric acid, lactic acid, tartaric acid, malonic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, cyclohexylsulfamic acid, fumaric acid, and quinic acid.
  • acids such as hydrochloric acid, maleic acid, sulfuric acid, phosphoric acid, sulfamic acid, acetic acid, citric acid, lactic acid, tartaric acid, malonic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, cyclohexylsulfamic acid, fumaric acid, and quinic acid.
  • Pharmaceutically acceptable salts also include basic addition salts such as those containing benzathine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine, procaine, aluminum, calcium, lithium, magnesium, potassium, sodium, ammonium, alkylamine, and zinc, when acidic functional groups, such as carboxylic acid or phenol are present.
  • the present invention provides compounds of Formula (I) above, which can be prepared using standard techniques. An overall strategy for preparing preferred compounds described herein can be carried out as described in this section. The examples which follow illustrate the synthesis of specific compounds. Using the protocols described herein as a model, one of ordinary skill in the art can readily produce other compounds of the present invention.
  • Nuclear magnetic resonance spectra were recorded at either 250 or 400 MHz using, respectively, a Bruker AM 250 or Bruker AC 400 spectrometer.
  • CDCI3 is deuteriochloroform
  • DMSO-d6 is hexadeuteriodimethylsulfoxide
  • CD3OD is tetradeuteriomethanol. Chemical shifts are reported in parts per million (•) downfield from the internal standard tetramethylsilane.
  • ODS refers to an octadecylsilyl derivatized silica gel chromatographic support. 5 ⁇ Apex-ODS indicates an octadecylsilyl derivatized silica gel chromatographic support having a nominal particle size of 5 ⁇ , made by Jones Chromatography, Littleton, Colorado.
  • YMC ODS-AQ® is an ODS chromatographic support and is a registered trademark of YMC Co. Ltd., Kyoto, Japan.
  • PRP-1® is a polymeric (styrene-divinylbenzene) chromatographic support, and is a registered trademark of Hamilton Co., Reno, Nevada)
  • Celite® is a filter aid composed of acid-washed diatomaceous silica, and is a registered trademark of Manville Corp., Denver, Colorado.
  • a compound of Formula (I) or a pharmaceutically acceptable salt thereof for the treatment of humans and other mammals, it is normally formulated in accordance with standard pharmaceutical practice as a pharmaceutical composition.
  • the calcilytic compounds can be administered by different routes including intravenous, intraperitoneal, subcutaneous, intramuscular, oral, topical (transdermal), or transmucosal administration.
  • oral administration is preferred.
  • the compounds can be formulated into conventional oral dosage forms such as capsules, tablets, and liquid preparations such as syrups, elixirs, and concentrated drops.
  • injection parenteral administration
  • the compounds of the invention are formulated in liquid solutions, preferably, in physiologically compatible buffers or solutions, such as saline solution, Hank's solution, or Ringer's solution.
  • the compounds may be formulated in solid form and redissolved or suspended immediately prior to use. Lyophilized forms can also be produced.
  • Systemic administration can also be by transmucosal or transdermal means.
  • penetrants appropriate to the barrier to be permeated are used in the formulation.
  • penetrants are generally known in the art, and include, for example, for transmucosal administration, bile salts and fusidic acid derivatives.
  • detergents may be used to facilitate permeation.
  • Transmucosal administration for example, may be through nasal sprays, rectal suppositories, or vaginal suppositories.
  • the compounds of the invention can be formulated into ointments, salves, gels, or creams, as is generally known in the art.
  • the amounts of various calcilytic compounds to be administered can be determined by standard procedures taking into account factors such as the compound IC50, EC50, the biological half-life of the compound, the age, size and weight of the patient, and the disease or disorder associated with the patient. The importance of these and other factors to be considered are known to those of ordinary skill in the art.
  • Amounts administered also depend on the routes of administration and the degree of oral bioavailability. For example, for compounds with low oral bioavailability, relatively higher doses will have to be administered.
  • the composition is in unit dosage form.
  • a tablet, or capsule may be administered, for nasal application, a metered aerosol dose may be administered, for transdermal application, a topical formulation or patch may be administered and for transmucosal delivery, a buccal patch may be administered.
  • dosing is such that the patient may administer a single dose.
  • Each dosage unit for oral administration contains suitably from 0.01 to 500 mg/Kg, and preferably from 0.1 to 50 mg/Kg, of a compound of Formula (I) or a
  • the daily dosage for parenteral, nasal, oral inhalation, transmucosal or transdermal routes contains suitably from 0.01 mg to 100 mg/Kg, of a compound of Formula(I).
  • a topical formulation contains suitably 0.01 to 5.0% of a compound of Formula (I).
  • the active ingredient may be administered, for example, from 1 to 6 times per day, preferably once, sufficient to exhibit the desired activity, as is readily apparent to one skilled in the art.
  • treatment of a disease includes, but is not limited to prevention, retardation and prophylaxis of the disease.
  • Diseases and disorders which might be treated or prevented, based upon the affected cells include bone and mineral-related diseases or disorders; hypoparathyroidism; those of the central nervous system such as seizures, stroke, head trauma, spinal cord injury, hypoxia-induced nerve cell damage, such as occurs in cardiac arrest or neonatal distress, epilepsy, neurodegenerative diseases such as Alzheimer's disease, Huntington's disease and Parkinson's disease, dementia, muscle tension, depression, anxiety, panic disorder, obsessive-compulsive disorder, post-traumatic stress disorder, schizophrenia, neuroleptic malignant syndrome, and Tourette's syndrome; diseases involving excess water reabsorption by the kidney, such as syndrome of inappropriate ADH secretion (SIADH), cirrhosis, congestive heart failure, and nephrosis; hypertension; preventing and/or decreasing renal toxicity from cationic antibiotics (e.g., aminoglycoside), amino
  • the present compounds are used to increase serum parathyroid hormone ("PTH") levels.
  • PTH serum parathyroid hormone
  • Increasing serum PTH levels can be helpful in treating diseases such as hypoparathyroidism, osteosarcoma, periodontal disease, fracture, osteoarthritis, rheumatoid arthritis, Paget's disease, humoral hypercalcemia malignancy and osteoporosis.
  • Another aspect of the present invention describes a method of treating a patient comprising administering to the patient an amount of a present compound sufficient to increase the serum PTH level.
  • the method is carried out by
  • the compound administered to a patient causes an increase in serum PTH having a duration of up to one hour, about one to about twenty-four hours, about one to about twelve hours, about one to about six hours, about one to about five hours, about one to about four hours, about two to about five hours, about two to about four hours, or about three to about six hours.
  • the compound administered causes an increase in serum PTH of longer than about twenty-four hours, but the compound is co-administered with an anti-resorptive agent.
  • the compound administered to a patient causes an increase in serum PTH of up to two fold, two to five fold, five to ten fold, and at least 10 fold, greater than peak serum PTH in the patient.
  • the peak serum level is measured with respect to a patient not undergoing treatment.
  • Composition of Formula (I) and their pharmaceutically acceptable salts which are active when given orally, can be formulated as syrups, tablets, capsules and lozenges.
  • a syrup formulation will generally consist of a suspension or solution of the compound or salt in a liquid carrier for example, ethanol, peanut oil, olive oil, glycerine or water with a flavoring or coloring agent. Where the composition is in the form of a tablet, any pharmaceutical carrier routinely used for preparing solid formulations may be used.
  • any routine encapsulation is suitable, for example using the aforementioned carriers in a hard gelatin capsule shell.
  • any pharmaceutical carrier routinely used for preparing dispersions or suspensions may be considered, for example aqueous gums, celluloses, silicates or oils, and are incorporated in a soft gelatin capsule shell.
  • Typical parenteral compositions consist of a solution or suspension of a compound or salt in a sterile aqueous or non-aqueous carrier optionally containing a parenterally acceptable oil, for example polyethylene glycol, polyvinylpyrrolidone, lecithin, arachis oil or sesame oil.
  • a parenterally acceptable oil for example polyethylene glycol, polyvinylpyrrolidone, lecithin, arachis oil or sesame oil.
  • compositions for inhalation are in the form of a solution, suspension or emulsion that may be administered as a dry powder or in the form of an aerosol using a conventional propellant such as dichlorodifluoromethane or trichlorofluoromethane.
  • a typical suppository formulation comprises a compound of Formula (I) or a pharmaceutically acceptable salt thereof which is active when administered in this way, with a binding and/or lubricating agent, for example polymeric glycols, gelatins, cocoa-butter or other low melting vegetable waxes or fats or their synthetic analogs.
  • Typical dermal and transdermal formulations comprise a conventional aqueous or non-aqueous vehicle, for example a cream, ointment, lotion or paste or are in the form of a medicated plaster, patch or membrane.
  • the composition is in unit dosage form, for example a tablet, capsule or metered aerosol dose, so that the patient may administer a single dose. No unacceptable toxological effects are expected when compounds of the present invention are administered in accordance with the present invention.
  • Sulfate- and phosphate-free parathyroid cell buffer contains 20 mM Na-Hepes, pH 7.4, 126 mM NaCl, 5 mM KCl, and 1 mM MgCl 2 .
  • SPF-PCB was made up and stored at 4 °C. On the day of use, SPF-PCB was supplemented with 1 mg/mL of D-glucose and 1 mM CaCl2 and then split into two fractions. To one fraction, bovine serum albumin (BSA; fraction V, ICN) was added at 5 mg/mL (SPF-PCB+). This buffer was used for washing, loading and maintaining the cells. The BSA-free fraction was used for diluting the cells in the cuvette for measurements of fluorescence.
  • BSA bovine serum albumin
  • the pellet was resuspended in 10 mL of SPF-PCB+ containing 2.2 uM fluo-3 (Molecular Probes) and incubated at room temperature for 35 minutes.
  • test compound or vehicle as a control
  • Calcilytic compounds were detected by their ability to block, in a concentration-dependent manner, increases in the concentration of intracellular Ca + elicited by extracellular Ca2 + .
  • those compounds having lower IC50 values in the Calcium Receptor Inhibitor Assay are more preferred compounds.
  • Compounds having an IC50 greater than 50 uM were considered to be inactive.
  • Preferred compounds are those having an IC50 of lOuM or lower, more preferred compounds have an IC50 of luM, and most preferred compounds have an IC50 of 0.1 uM or lower.
  • HEK 2934.0-7 cells stably transfected with the Human Parathyroid Calcium Receptor("HuPCaR”) were scaled up in T 180 tissue culture flasks.
  • Plasma membrane is obtained by polytron homogenization or glass douncing in buffer (50mM Tris-HCl pH 7.4, ImM EDTA, 3mM MgCl2) in the presence of a protease inhibitor cocktail containing luM Leupeptin, 0.04 uM Pepstatin, and 1 mM PMSF. Aliquoted membrane was snap frozen and stored at -80°C.
  • ⁇ H labeled compound was radiolabeled to a radiospecific activity of 44Ci/mmole and was aliquoted and stored in liquid nitrogen for radiochemical stability.
  • a typical reaction mixture contains 2 nM ⁇ H compound ((R,R)-N-4 -
  • Nonspecific binding is determined by the addition of 100-fold excess of unlabeled homologous ligand, and is generally 20% of total binding.
  • the binding reaction is terminated by rapid filtration onto 1% PEI pretreated GF/C filters using a Brandel Harvestor. Filters are placed in scintillation fluid and radioactivity assessed by liquid scintillation counting.
  • 2-(4-Amino-4-methylpentyl)pyridine To 2-bromopyridine (0.948 g, 6 mmole) was added 9-(4-benzyloxycarbonylamino- 4-methylpentyl)-9-borabicyclo[3.3.1]nonane (12 mL, 5 mmole of a THF solution) in a nitrogen flushed reaction tube. To this solution was added 0.122 g (0.15 mmole) of [ 1 , 1 ' -bis(diphenylphosphino)ferrocene]dichloropalladium(II) dichloromethane complex (1:1), 1.38 g (10 mmole) of potassium carbonate, and 1.25 mL of water.
  • the reaction was stirred for 18 hours at 65 C, then poured into aqueous NaOH, and extracted with ether. The ether layer was separated, washed with brine, dried over sodium sulfate, and concentrated in vacuo.
  • the crude product was taken up in 20 mL of ethanol to which 1 g of palladium hydroxide on carbon (10%) was added. The mixture was stirred for 18 hours under a hydrogen balloon. The reaction mixture was filtered and concentrated in vacuo. The residue was taken up in aqueous HCI, and extracted with ether. The aqueous layer was separated, made basic with NaOH, and extracted with ether.
  • the reaction was stirred for 16.5 hours at 50 C, then poured into aqueous NaOH, and extracted with ether. The ether layer was separated, washed with brine, dried over sodium sulfate, and concentrated in vacuo.
  • the crude product was taken up in 10 mL of ethanol to which 0.3 g of palladium hydroxide on carbon (10%) was added. The mixture was stirred for 18 hours under a hydrogen balloon. The reaction mixture was filtered and concentrated in vacuo. The residue was taken up in aqueous HCI, and extracted with ether. The aqueous layer was separated, made basic with NaOH, and extracted with ether. The ether layer was dried over sodium sulfate, and concentrated in vacuo to give crude ethyl 2-(4-amino-4-methylpentyl)benzoate.
  • Formulations for pharmaceutical use inco ⁇ orating compounds of the present invention can be prepared in various forms and with numerous excipients. Examples of such formulations are given below.
  • a compound of Formula (I) (1 mg to 100 mg) is aerosolized from a metered dose inhaler to deliver the desired amount of drug per use.
  • Ingredients 1, 2, 3 and 4 are blended in a suitable mixer/blender. Sufficient water is added portion-wise to the blend with careful mixing after each addition until the mass is of a consistency to permit its conversion to wet granules.
  • the wet mass is converted to granules by passing it through an oscillating granulator using a No. 8 mesh (2.38 mm) screen.
  • the wet granules are then dried in an oven at 140°F (60°C) until dry.
  • the dry granules are lubricated with ingredient No. 5, and the lubricated granules are compressed on a suitable tablet press.
  • a pharmaceutical composition for parenteral administration is prepared by dissolving an appropriate amount of a compound of Formula (I) in polyethylene glycol with heating. This solution is then diluted with water for injections (to 100 ml). The solution is then rendered sterile by filtration through a 0.22 micron membrane filter and sealed in sterile containers. All publications, including but not limited to patents and patent applications cited in this specification are herein inco ⁇ orated by reference as if each individual publication were specifically and individually indicated to be inco ⁇ orated by reference as though fully set forth.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Quinoline Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Furan Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Calcilytic compounds and compositions and their use in treating abnormal bone or mineral homeostasis.

Description

CALCILY IC COMPOUNDS AND METHOD OF USE
FTF.T.r) nF TNVF.NTTnN The present invention relates to novel calciiytic compounds, pharmaceutical compositions containing these compounds and their use as calcium receptor antagonists.
In mammals, extracellular Ca^+ is under rigid homeostatic control and regulates various processes such as blood clotting, nerve and muscle excitability, and proper bone formation. Extracellular Ca^+ inhibits the secretion of parathyroid hormone ("PTH") from parathyroid cells, inhibits bone resorption by osteoclasts, and stimulates secretion of calcitonin from C-cells. Calcium receptor proteins enable certain specialized cells to respond to changes in extracellular Ca^+ concentration.
PTH is the principal endocrine factor regulating Ca^+ homeostasis in the blood and extracellular fluids. PTH, by acting on bone and kidney cells, increases the level of Ca^+ in the blood. This increase in extracellular Ca^+ then acts as a negative feedback signal, depressing PTH secretion. The reciprocal relationship between extracellular Ca^+ and PTH secretion forms an important mechanism maintaining bodily C ^+ homeostasis. Extracellular Ca^+ acts directly on parathyroid cells to regulate PTH secretion. The existence of a parathyroid cell surface protein which detects
2+ changes in extracellular Ca has been confirmed. See Brown et al., Nature
366:51 A, 1993. In parathyroid cells, this protein, the calcium receptor, acts as a
2+ receptor for extracellular Ca , detects changes in the ion concentration of extracellular Cd?-+ , and initiates a functional cellular response, PTH secretion.
Extracellular Ca2+ influences various cell functions, reviewed in Nemeth et al., Cell Calcium 11:319, 1990. For example, extracellular Ca2+ plays a role in parafollicular (C-cells) and parathyroid cells. See Nemeth, Cell Calcium 11:323, 1990. The role of extracellular Ca^+ on bone osteoclasts has also been studied. See Zaidi, Bioscience Reports 10:493, 1990.
Various compounds are known to mimic the effects of extra-cellular Cd -+ on a calcium receptor molecule. Calcilytics are compounds able to inhibit calcium receptor activity, thereby causing a decrease in one or more calcium receptor activities evoked by extracellular Ca + . Calcilytics are useful as lead molecules in the discovery, development, design, modification and/or construction of useful calcium modulators which are active at Ca + receptors. Such calcilytics are useful in the treatment of various disease states characterized by abnormal levels of one or more components, e.g., polypeptides such as hormones, enzymes or growth factors, the expression and/or secretion of which is regulated or affected by activity at one or more Ca + receptors. Target diseases or disorders for calcilytic compounds include diseases involving abnormal bone and mineral homeostasis.
Abnormal calcium homeostasis is characterized by one or more of the following activities: an abnormal increase or decrease in serum calcium; an abnormal increase or decrease in urinary excretion of calcium; an abnormal increase or decrease in bone calcium levels (for example, as assessed by bone mineral density measurements); an abnormal absorption of dietary calcium; an abnormal increase or decrease in the production and/or release of messengers which affect serum calcium levels such as PTH and calcitonin; and an abnormal change in the response elicited by messengers which affect serum calcium levels.
Thus, calcium receptor antagonists offer a unique approach towards the pharmacotherapy of diseases associated with abnormal bone or mineral homeostasis, such as hypoparathyroidism, osteosarcoma, periodontal disease, fracture healing, osteoarthritis, rheumatoid arthritis, Paget's disease, humoral hypercalce ia associated with malignancy and fracture healing, and osteoporosis.
SUMMARY OF THE INVENTION
The present invention comprises novel calcium receptor antagonists represented by Formula (I) hereinbelow and their us in the treatment of a variety of diseases associated with abnormal bone or mineral homeostasis, including but not limited to hypoparathyroidism, osteosarcoma, periodontal disease, fracture healing, osteoarthritis, rheumatoid arthritis, Paget's disease, humoral hypercalcemia associated with malignancy and fracture healing, and osteoporosis.
The present invention further provides a method for antagonizing calcium receptors in an animal, including humans, which comprises administering to an animal in need thereof an effective amount of a compound of Formula (I), indicated hereinbelow.
The present invention further provides a method for increasing serum parathyroid levels in an animal, including humans, which comprises administering to an animal in need thereof an effective amount of a compound of Formula (I), indicated hereinbelow.
DETAILED DESCRIPTION OF THE INVENTION
The compounds of the present invention are selected from Formula (I) hereinbelow:
R3\ /R4 ,- Λ X: vf R 7 X R8 X Formula (I)
wherein:
Y is a covalent bond, alkylene or alkenylene of up to 4 carbon atoms, unsubstituted or substituted by C 1.4 alkyl or O;
Y2 is methylene, unsubstituted or substituted by C 1.4 alkyl or haloalkyl;
Y3 is covalent bond or O, S, N-R^ or C1.4 alkylene-O, Cj_4 alkylene-S, C1.4 alkylene-N-RΪV ;
RΪ is selected from the group consisting of H, Cj_4 alkyl, C3.6 cycloalkyl;
R3 and R4 are, independently, methyl or ethyl, or, together, form cyclopropyl;
R5 is heteroaryl or fused heteroaryl; wherein the hetero-ring contains N, O or S, and is aromatic, dihydro or tetrahydro, unsubstituted or substituted with any substituents being selected from the group consisting of OH, OCH3, CH(CH3)2, halogen, Cι_4 alkyl, Cj_4 alkoxy, C3.6 cycloalkyl, OS02RIV, CN, N02, OCF3,
CF3, CH2CF3, (CH2)n C02H, (CH2)n C02RIV, and 0-(CH2)n C02RIV; n is an integer from 0 to 3;
G is a covalent bond, CHRg or C-Rg ,wherein Rg is H, OH or O (forming a ketone); R7 is H, OH, or 0-Cι_4 alkyl;
Rg is H or Cι_4 alkyl; or R7 and Rg together form a ketone;
A and B are, independently, selected from the group consisting of a bond, CH2,
NH, O, S and C=0, provided that either A or B is selected from CH2 and NH; or A and B together form a bond; or the A-B moiety is represented by CH=CH or C≡C;
X is selected from sub formulas (la) to (Ie) hereinbelow:
Figure imgf000006_0001
(la)
Figure imgf000006_0002
(Ib)
Figure imgf000006_0003
(Ic) 1
Figure imgf000007_0001
(Id)
Figure imgf000007_0002
(le)
wherein
W is selected from the group consisting of Ri , SO2R1, C(0)Rι, SO2NR1R1 , C(0)NRιRι', C(0)ORι, SO3R1', wherein R^ and Ri 'are independently selected from the group consisting of hydrogen, Cj_4 alkyl, C3.6 cycloalkyl, C2.5 alkenyl, C2.5 alkynyl, heterocycloalkyl, aryl and aryl C1.4 alkyl; or R\ and Ri together form a 3 to 7 membered optionally substituted heterocyclic ring; wherein any substituents are selected from the group consisting of CN, aryl, CO2R, CO2NHR, OH, OR, NH2, halo, CF3, OCF3 and N02; wherein R represents Cι_4 alkyl, or C3. g cycloalkyl; Xi is selected from the group consisting of CN, NO2, Cl, F, Br, I, H, R\ OR', CF3, OCF3 and OSO2R', wherein R' represents C}_4 alkyl, or C3.6 cycloalkyl; X2 , X3 and X4 are, independently, selected from the group consisting of CN, N02, Cl, F, Br, I, H, R", OR", CF3, OCF3 and OS02R", provided that either X! or X3 is H, wherein R" is Cμ4 alkyl or haloalkyl; or Xj and X2 together form an aryl or heteroaryl ring, substituted or unsubstituted; wherein the heteroatom is selected from N, S and O; and any substituents are selected from the group consisting of halo, Cι_4 alkyl, OCF3, CF3, OMe, CN, OS02R' and N02; or X3 and X4 independently represent C(0)Rι; and
5 R2 is selected from the group consisting of hydrogen, Cj_4 alkyl, C3.6 cycloalkyl, C2-5 alkenyl, C2-5 alkynyl, heterocycloalkyl aryl and aryl-Ci.4 alkyl; Xj" is selected from the group consisting of CN, NO2, Cl, F, Br, I, H, R, OR, CF3, OCF3 and OSO2R, wherein R represents C ^ alkyl, or C3.6 cycloalkyl; X2", X3" and X4" are, independently, selected from the group consisting of CN, N02, Cl, F, Br, I, H, R\ OR', CF3, OCF3 and OS02R\ provided that either X"! or X"3 is H, wherein R' is C 1.4 alkyl or haloalkyl; or Xi ' and X2" together form an aryl or heteroaryl ring, substituted or unsubstituted; wherein the heteroatom is selected from N, S and O and any substituents are selected from the group consisting of halo, Cj_4 alkyl, OCF3, CF3, OMe, CN, OS02-Cι_4 alkyl, OSO2- C3-6 cycloalkyl and NO2; or X3" and X4" independently represent C(0)Rι ; and
Rj" and R2" are, independently, selected from the group consisting of hydrogen, Cj_4 alkyl, C3.6 cycloalkyl, C2.5 alkenyl, C2.5 alkynyl, heterocycloalkyl and aryl; or Rj" and R2" together form a 3 to 7 membered optionally substituted heterocyclic ring; wherein any substituents are selected from the group consisting of CN, aryl, C02R", C02NHR", OH, OR", NH2, halo, CF3, OCF3 and N02; wherein R" represents \_^ alkyl, or C3.6 cycloalkyl; X m is selected from the group consisting of CN, NO2, Cl, F, Br, I, H, R, OR, CF3, OCF3 and OSO2R, wherein R represents C^_4 alkyl, or C3.6 cycloalkyl;
X2"', X3"', and X4"' are, independently, selected from the group consisting of CN, N02, Cl, F, Br, I, H, R', OR', CF3, OCF3 and OS02R', provided that either m\ or X"'3 is H, wherein R' is Cj_4 alkyl or haloalkyl; or Xi '" and X2'" together form an aryl or heteroaryl ring, substituted or unsubstituted; wherein the heteroatom is selected from N, S and O and the substituents are selected from the group consisting of halo, C1.4 alkyl, OCF3, CF3,
OMe, CN, OS02-Cι_4 alkyl, OSO2-C3.6 cycloalkyl and N02; or X3"' and X4 '" independently represent C(0)Rι ;
Rj'" and R2" are, independently, selected from the group consisting of hydrogen, C 4 alkyl, C3.6 cycloalkyl, C2.5 alkenyl, C2-5 alkynyl, heterocycloalkyl and aryl; or Rι'"and R2"' together form a 3 to 7 membered optionally substituted heterocyclic ring; wherein the substituents are selected from the group consisting of CN, aryl, C02R", C02NHR", OH, OR", NH2, halo, CF3, OCF3 and N02; wherein
R" represents Cι_4 alkyl, or C3.6 cycloalkyl;
D is selected from the group consisting of H, CN, NO2, Cl, F, Br, I, R, OR, SR,
CF3, OCF3 and OSO2R, wherein R represents C1.4 alkyl, C3.6 cycloalkyl, or Cι_ 10 aryl or heteroaryl wherein the heteroatom is selected from N, S and O and substituents are selected from the group consisting of halo, C1.4 alkyl, OCF3, CF3,
OMe, CN, OSO2-C1.4 alkyl, OS02-
C3-6 cycloalkyl and NO2; n is the integer 1 or 2; each E is independently C or N, provided that no more than two E moieties are N; further provided that when n is 2, each E is C; a and b are optionally present bonds;
Ri ^ is selected from the group consisting of (CH2)nCθ2R\ (CH2)nCθ2H,
(CH2)nCONR'2, (CH2)nCH2OR', OR', SR', CN, N02, Cl, F, Br, I, H, CF3, OCF3, OSO2R', R' and H; wherein R' represents C\_4 alkyl, or C3.6 cycloalkyl; or R\ " is O, forming a ketone such that Y Ri w represents -C=0;
R2™ is selected from the group consisting of hydrogen, CN, NO2 Cl, F, Br, I, H,
R", OR", CF3, OCF3, and OSO2R"; wherein R" represents C\_4 alkyl, or C3.6 cycloalkyl. Y is selected from the group consisting of C, CH, O, N and S; provided that when
Y is S, R\ ,v is O or not present; further provided that when Y is O, R\ 1V is not present;
X' is selected from the group consisting of CH2, NH, O and S.
R9 is selected from the group consisting of O-alkyl, 0-CH2-aryl, and O- aryl; X\"" is selected from the group consisting of CN, NO2, Cl, F, Br, I, H, R, OR,
CF3, OCF3 and OSO2R, wherein R represents C1.4 alkyl, or C3.6 cycloalkyl;
X2'"', X3"", and X4"" are, independently, selected from the group consisting of CN,
N02, Cl, F, Br, I, H, R', OR', CF3, OCF3 and OS02R', provided that either X""! or
X""3 is H, wherein R' is C1.4 alkyl or haloalkyl; or X 1 "" and X2"" together form an aryl or heteroaryl ring, substituted or unsubstituted; wherein the heteroatom is selected from N, S and O and the substituents are selected from the group consisting of halo, Ci .4 alkyl, OCF3, CF3,
OMe, CN, OSθ2-Cμ4 alkyl, OS02-C3.6 cycloalkyl and N0 ; or X2"" and X4 "" independently represent C(0)Rι; and pharmaceutically acceptable salts and complexes thereof.
Preferably, the compounds of the present invention have a structure according to Formula (H):
Figure imgf000010_0001
Formula (II) wherein: R5 is heteroaryl or fused heteroaryl; wherein the hetero-ring contains N, O or S, and is aromatic, dihydro or tetrahydro, unsubstituted or substituted with any substituents being selected from the group consisting of OH, OCH3, CH(CH3)2, halogen, C _4 alkyl, C^ alkoxy, C3_6 cycloalkyl, OSθ2RIV, CN, N02, OCF3, CF3, CH2CF3, (CH2)n C02H, (CH2)n C02RIV, and 0-(CH2)n C02RIV; and A and B are, independently, selected from the group consisting of a bond, CH2, NH, O, S and C=0, provided that either A or B is selected from CH2 and NH; or A and B together form a bond; or the A-B moiety is represented by CH=CH or C≡C. More preferably, R5 is heteroaryl or fused heteroaryl, wherein the hetero- ring contains N, O or S and is aromatic, dihydro or tetrahydro, unsubstituted or substituted with any substituents being selected from the group consisting of OCH3, halogen, Cμ4 alkyl, , CN, N02, OCF3, CF3, CH2CF3; Rg is H; and
A and B are, independently, selected from the group consisting of a bond, CH2, NH, O, S and C=0, provided that either A or B is selected from CH2 and NH, or A and B together form a bond. Most preferably, R5 is heteroaryl or fused heteroaryl, wherein the hetero-ring contains N, O or S and is aromatic, dihydro or tetrahydro, unsubstituted or substituted with any substituents being selected from the group consisting of OCH3, halogen, Cχ.4 alkyl, , CN, N02, OCF3, CF3, CH2CF3; Rg is H; and A and B are, independently, selected from the group consisting of a bond, CH2, 0, or A and B together form a bond. In sub-formula (la), preferably, Xj is selected from the group consisting of CN, NO2, Cl, F, Br, I and H. Preferably, X2, X3 and X4 are, independently, selected from the group consisting of Cl, F, Br, I and H, provided X^ and X3 is H. Preferably, R\, Rj'and R2 are, independently, selected from the group consisting of C1.4 alkyl, C3.6 cycloalkyl, heterocycloalkyl, aryl or arylalkyl.
In sub-formula (la), more preferably, R\, Rj'and R2 are, independently, H, alkyl, or aryl. More preferably, X\ is selected from the group consisting of CN, NO2, Cl, F, Br, I and H. More preferably, X2, X3 and X4 are, independently, selected from the group consisting of Cl, F, Br, I and H provided X j and X3 is H. In sub-formula (la), more preferably still, R , Ri 'and R2 are, independently, C .^ alkyl, or aryl. More preferably still, X\ is CN, NO2, or Cl. More preferably still, X2 is Cl, F or H. More preferably still, X3 and X4 are H.
In sub-formula (la), most preferably, X\ is CN, or NO2. Most preferably, X2 is Cl. In sub-formula (Ib), preferably, Xi " is selected from the group consisting of CN, NO2, Cl, F, Br, I and H. Preferably, X2", X3" and X4" are, independently, selected from the group consisting of Cl, F, Br, I and H. Preferably, R\" and R2" are, independently, selected from the group consisting of C 1.4 alkyl, C3.6 cycloalkyl, heterocycloalkyl or aryl; or Ri " and R2" together form an optionally substituted 3-7 membered ring, optionally containing an additional heteroatom selected from O, S, and N.
In sub-formula (Ib), more preferably, Ri " and R2" are, independently, H, C1.4 alkyl, or aryl; or R\ " and R2" together form an optionally substituted 4-7 membered ring, optionally containing a heteroatom selected from O, S, and N. More preferably, Xi " is selected from the group consisting of CN, NO2, Cl, F, Br, I and H. More preferably, X2" is selected from the group consisting of Cl, F, Br, I and H.
In sub-formula (Ib), more preferably still, Ri 'and R2" are, independently, Cι_4 alkyl, or aryl; or R\" and R2" together form a 4-7 membered ring as described hereinabove. More preferably still, X\" is CN, NO2, or Cl. More preferably still, X2" is Cl, F or H. In sub-formula (Ib), most preferably, R " and R2" together form a 4-7 membered ring as described hereinabove. Most preferably, X\" is CN, or Nθ2- Most preferably, X2 "is Cl.
In sub-formula (Ic), preferably, Xi™ is selected from the group consisting of CN, NO2, Cl, F, Br, I and H. Preferably, X2'", X^ and X4m are, independently, selected from the group consisting of Cl, F, Br, I and H. provided either X\ "Or X3m is H. Preferably, R\ m and R2"' are, independently, selected from the group consisting of Cj_4 alkyl, C3.6 cycloalkyl, heterocycloalkyl or aryl; or R\m and R2"' together form an optionally substituted 3-7 membered ring, optionally containing an additional heteroatom selected from O, S, and N.
In sub-formula (Ic), more preferably, R\ m, and R2"' are, independently, H, Cj_4 alkyl, or aryl; or Rj"' and R2"' together form an optionally substituted 4-7 membered ring, optionally containing a heteroatom selected from O, S, and N. More preferably, X\ m is selected from the group consisting of CN, NO2, Cl, F, Br, I and H. More preferably, X^, X3™ and X4™ are, independently, selected from the group consisting of Cl, F, Br, I and H provided either X "' or X3"' is H.
In sub-formula (Ic), more preferably still, Rι"'and R2™ are, independently, Cι_4 alkyl, or aryl; or R}'" and R2"' together form a 4-7 membered ring as described hereinabove. More preferably still, Xi™ is CN, NO2, or Cl. More preferably still, X2 " is Cl or H. More preferably still, X3'" and X4'" are H.
In sub-formula (Ic), most preferably, Ri '" and R2'" together form a 4-7 membered ring as described hereinabove. Most preferably, X\m is CN or NO2. Most preferably, X2 '" is Cl.
In sub-formula (Id), preferably, each D is selected from the group consisting of F, Br, Cl, I, R, OR, SR, and H. Preferably, Ri ,v is selected from the group consisting of (CH2)nC02R', (CH2)nC02H, (CH2)nCONR 2, (CH2)nCH2θR', OR', SR', R' and H; wherein R' is as R hereinabove; or Rγ ,v is O, forming a ketone such that Y R^ IV represents -C=0. Preferably, R2*v is selected from the group consisting of hydrogen, CN, NO2 Cl, Br, F and I; In sub-formula (Id), more preferably, n is O. More preferably, each E is C.
More preferably, X' is CH2, O, or NH. More preferably, Y is C or N. More preferably, Ri ιv is CH2CO2R', SR', or O forming a ketone.
10 In subformula (Id), more preferably still, X' is CH2 or O. More preferably still, Ri 1V is CH2C02R' or SR'. More preferably still, R2'v is H, CN, or N02.
In subformula (Id), most preferably, X' is CH2. Most preferably, Y is C.
Most preferably, R2<v is CN or NO2. In subformula (Ie), preferably R9 is selected from the group consisting of
0-(CH2)n-aryl, and O- aryl;
Xi "" is selected from the group consisting of CN, NO2, Cl, F, Br, H, R, and
OSO2R, wherein R represents \.4 alkyl, or C3.6 cycloalkyl;
X2"", X3"", and X4"" are, independently, selected from the group consisting of CN, NO2, Cl, F, Br, H,and OS02R', provided that either X""ι or X""3 is H, wherein R' is Cj_4 alkyl or haloalkyl; or Xj "" and X2"" together form an aryl or heteroaryl ring, substituted or unsubstituted; wherein the heteroatom is selected from N, S and O and the substituents are selected from the group consisting of halo, Cμ4 alkyl, OCF3, CF3, OMe, CN, OSθ2-C!.4 alkyl, OSO2-C3.6 cycloalkyl and N02; or X2"" and X4 "" independently represent C(0)Rj;
In subformula (Ie), more preferably R9 is selected from the group consisting of 0-(CH2)n-aryl, and O- aryl;
Xi "" is selected from the group consisting of CN, NO2, and Cl X2"". X3"". and X4"" are, independently, selected from the group consisting of Cl,
F, and H, provided that either X""ι or X""3 is H, or X2"" and X4 "" independently represent C(0)Rι;
In subformula (Ie), most preferably R9 is selected from the group consisting of 0-(CH2)n-aryl, and O- aryl; X1"" is CN or Nθ2,
X2" " is Cl, X3"" and X4"" are, independently F, and H.
Preferred heteroaryls useful in the present invention include unsubstituted and substituted quinolines, isoquinolines, benzofurans, dihydrobenzofurans, benzothiophenes, dihydrobenzothiophenes and pyridines. As used herein "cycloalkyl" refers to optionally substituted 3-7 membered carbocyclic rings wherein any substituents are selected from the group consisting of, F, Cl, Br, I, N(Rj)2, SRj and ORi, unless otherwise indicated.
11 As used herein "heterocycloalkyl" refers to optionally substituted 4, 5, 6 or 7 membered heterocyclic rings containing 1 to 2 heteroatoms selected from N, O, and S.
As used herein, "aryl" refers to an optionally substituted aromatic group with at least one ring having a conjugated pi-electron system, containing up to two conjugated or fused ring systems. Aryl includes carbocyclic aryl, and biaryl groups, all of which may be optionally substituted. Preferred aryl include phenyl and naphthyl. More preferred aryl include phenyl. Preferred substituents are selected from the group consisting of halo, Cj_4 alkyl, OCF3 CF3 OMe, CN, OSθ2 R nd Nθ2 wherein R represents \^ alkyl or C3.6 cycloalkyl.
As used herein, "acyl" refers to C1.4 alkylcarbonyl.
As used herein, "alkenyl" refers to an optionally substituted hydrocarbon group containing at least one carbon-carbon double bond and containing upto 5 carbon atoms joined together. The alkenyl hydrocarbon chain may be straight, branched or cyclic. Any substituents are selected from the group consisting of halo, C1..4 alkyl, OCF35 CF3> OMe, CN, OSO2 R and N02, wherein R represents Cι_4 alkyl or C3.6 cycloalkyl.
As used herein, "alkynyl" refers to an optionally substituted hydrocarbon group containing at least one carbon-carbon triple bond between the carbon atoms and containing up to 5 carbon atoms joined together. The alkynyl hydrocarbon group may be straight-chained, branched or cyclic. Any substituents are selected from the group consisting of halo, Cμ4 alkyl, OCF3, CF3, OMe, CN, OSO2 R and NO2, wherein R represents C1.4 alkyl or C3.6 cycloalkyl.
The compounds of the present invention may contain one or more asymmetric carbon atoms and may exist in racemic and optically active forms. All of these compounds and diastereomers are contemplated to be within the scope of the present invention.
Preferred compounds of the present invention are selected from the group consisting of: (R)-N-[2-Hydroxy-3-(3-chloro-2-cyanophenoxy)propyl]-l,l-dimethyl-2-(2,3- dihydrobenzo[b]furan-5yl)ethylamine;
(R)-N-[2-Hydroxy-3-(3-chloro-2-cyanophenoxy)propyl]-l,l-dimethyl-2-(quinolin- 3-yl)ethylamine;
12 (R)-N-[2-Hydroxy-3-(3-chloro-2-cyanophenoxy)propyl]-l,l-dimethyl-2-(quinolin-
2-yl)ethylamine;
(R)-N-[2-Hydroxy-3-(3-chloro-2-cyanophenoxy)propyl]- 1 , l-dimethyl-2-
(isoquinolin-3-yl)ethylamine; (R)-N-[2-Hydroxy-3-(3-chloro-2-cyanophenoxy)propyl]- 1 , l-dimethyl-4-(2- pyridyl)butylamine;
(R)-N-[2-Hydroxy-3-(3-chloro-2-cyano-4- mo holinosulfonamidophenoxy)propyl]-l,l-dimethyl-4-(2-pyridyl)butylamine;
(R)-N-[2-Hydroxy-3-(3-chloro-2-cyanophenoxy)propyl]-l,l-dimethyl-4-(3- pyridyl)butylamine;
(R)-N-[2-Hydroxy-3-(3-chloro-2-cyano-4- morpholinosulfonamidophenoxy)propyl]- 1 , 1 -dimethyl-4-(3-pyridyl)butylamine;
(R)-N-[2-Hydroxy-3-(3-chloro-2-cyanophenoxy)propyl]- 1 , l-dimethyl-4-(4- carbethoxypheny butylamine; (R)-N- [2-Hydroxy-3-(3-chloro-2-cy anophenoxy)propy 1]- 1 , 1 -dimethyl-2-(4- ethylpyrid-2-yl)ethylamine;
(R)-N-[2-Hydroxy-3-(3-chloro-2-cyanophenoxy)propyl]- 1 , 1 -dimethyl-2- benzamidoethylamine;
(R)-N-[2-Hydroxy-3-(3-chloro-2-cyanophenoxy)propyl]-4-pheπylbutylamine; (R)-N-[2-Hydroxy-3-(3-chloro-2-cyanophenoxy)propyl]-l,l-dimethyl-4-phenylbut-
2-ynylamine; and pharmaceutically acceptable salts and complexes thereof. Preferred salts include hydrochloride and dihydrochloride.
More preferred compounds useful in the present invention include: (R)-N-[2-Hydroxy-3-(3-chloro-2-cyanophenoxy)propyl]-l,l-dimethyl-2-(2,3- dihydrobenzo[b]furan-5yl)ethylamine;
(R)-N-[2-Hydroxy-3-(3-chloro-2-cyanophenoxy)propyl]-l,l-dimethyl-2-(quinolin-
3-yl)ethylamine;
(R)-N-[2-Hydroxy-3-(3-chloro-2-cyanophenoxy)propyl]-l,l-dimethyl-2-(quinolin- 2-yl)ethylamine;
(R)-N-[2-Hydroxy-3-(3-chloro-2-cyanophenoxy)propyl]-l,l-dimethyl-2-
(isoquinolin-3-yl)ethylamine;
13 (R)-N-[2-Hydroxy-3-(3-chloro-2-cyanophenoxy)propyl]-l,l-dimethyl-4-(2- pyridyl)butylamine;
(R)-N-[2-Hydroxy-3-(3-chloro-2-cyano-4- moφholinosulfonamidophenoxy)propyl]-l,l-dimethyl-4-(2-pyridyl)butylamine; (R)-N-[2-Hydroxy-3-(3-chloro-2-cyanophenoxy)propyl]- 1 , 1 -dimethyl-4-(3- pyridyl)butylamine;
(R)-N-[2-Hydroxy-3-(3-chloro-2-cyano-4- morpholinosulfonamidophenoxy)propyl]-l,l-dimethyl-4-(3-pyridyl)butylamine;
(R)-N-[2-Hydroxy-3-(3-chloro-2-cyanophenoxy)propyl]-l,l-dimethyl-2-(4- ethylpyrid-2-yl)ethylamine;
(R)-N-[2-Hydroxy-3-(3-chloro-2-cyanophenoxy)propyl]-l,l-dimethyl-2- benzamidoethylamine;
(R)-N-[2-Hydroxy-3-(3-chloro-2-cyanophenoxy)propyl]-4-phenylbutylamine; and pharmaceutically acceptable salts and complexes thereof. The most preferred compounds useful in the present invention include:
(R)-N-[2-Hydroxy-3-(3-chloro-2-cyanophenoxy)propyl]-l,l-dimethyl-2-(2,3- dihydrobenzo[b]furan-5yl)ethylamine;
(R)-N-[2-Hydroxy-3-(3-chloro-2-cyanophenoxy)propyl]-l,l-dimethyl-2-(quinolin-
3-yl)ethylamine; (R)-N-[2-Hydroxy-3-(3-chloro-2-cyanophenoxy)propyl]-l,l-dimethyl-2-(quinolin-
2-yl)ethylamine;
(R)-N-[2-Hydroxy-3-(3-chloro-2-cyanophenoxy)propyl]-l,l-dimethyl-2-
(isoquinolin-3-yl)ethylamine;
(R)-N-[2-Hydroxy-3-(3-chloro-2-cyanophenoxy)propyl]-l,l-dimethyl-4-(2- pyridyl)butylamine;
(R)-N-[2-Hydroxy-3-(3-chloro-2-cyano-4- morpholinosulfonamidophenoxy)propyl]-l,l-dimethyl-4-(2-pyridyl)butylamine;
(R)-N-[2-Hydroxy-3-(3-chloro-2-cyanophenoxy)propyl]-l,l-dimethyl-4-(3- pyridyl)butylamine; (R)-N-[2-Hydroxy-3-(3-chloro-2-cyano-4- morpholinosulfonamidophenoxy)propyl]- 1 , 1 -dimethyl-4-(3-pyridyl)butylamine;
(R)-N-[2-Hydroxy-3-(3-chloro-2-cyanophenoxy)propyl]-l,l-dimethyl-2-(4- ethylpyrid-2-yl)ethylamine;
14 and pharmaceutically acceptable salts and complexes thereof.
Pharmaceutically acceptable salts are non-toxic salts in the amounts and concentrations at which they are administered.
Pharmaceutically acceptable salts include acid addition salts such as those containing sulfate, hydrochloride, fumarate, maleate, phosphate, sulfamate, acetate, citrate, lactate, tartrate, methanesulfonate, ethanesulfonate, benzenesulfonate, p- toluenesulfonate, cyclohexylsulfamate and quinate. A preferred salt is a hydrochloride. Pharmaceutically acceptable salts can be obtained from acids such as hydrochloric acid, maleic acid, sulfuric acid, phosphoric acid, sulfamic acid, acetic acid, citric acid, lactic acid, tartaric acid, malonic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, cyclohexylsulfamic acid, fumaric acid, and quinic acid.
Pharmaceutically acceptable salts also include basic addition salts such as those containing benzathine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine, procaine, aluminum, calcium, lithium, magnesium, potassium, sodium, ammonium, alkylamine, and zinc, when acidic functional groups, such as carboxylic acid or phenol are present.
The present invention provides compounds of Formula (I) above, which can be prepared using standard techniques. An overall strategy for preparing preferred compounds described herein can be carried out as described in this section. The examples which follow illustrate the synthesis of specific compounds. Using the protocols described herein as a model, one of ordinary skill in the art can readily produce other compounds of the present invention.
Scheme 1
Figure imgf000017_0001
15 Scheme 2
Figure imgf000018_0001
Figure imgf000018_0002
Figure imgf000018_0003
Figure imgf000018_0004
Scheme 3
10
DPPA, Benzyl alcohol 9-BBN, THF bz
Figure imgf000018_0005
Figure imgf000018_0007
OH
Figure imgf000018_0008
Figure imgf000018_0006
,Cbz
PdCI2(dppf) KjCOg, H20
Figure imgf000018_0009
2. Pdt H c,
EtOH
16 Scheme 4
1. NaH, DMSO
1. NaCN AcOH
-PPh, H2S04/AcOH »~
Figure imgf000019_0001
2. NaOH, EtOH
Figure imgf000019_0002
reflux 24h
Figure imgf000019_0003
General Preparation
A general procedure used to synthesize many of the compounds can be carried out as described in Scheme 1 : A solution of aryl alcohol in acetone was treated with an appropriate base such as K2CO3, heated for 15 min. R-glycidyl nosylate was added and the reaction continued overnight to give the corresponding glycidyl ether (Scheme 1). In the case of an alkyl alcohol, a stronger base, e.g. NaH in DMF was used. This method can also be used for aryl alcohols. A solution of the substituted glycidyl ether and excess amine (typically l,l-dimethyl-2-(4- methyloxyphenyl)ethylamine) in absolute ethanol, acetonitrile, THF or any other similar solvent in the presence of a suitable catalyst such as LiClθ4 is stirred overnight at reflux. The product is purified by normal phase chromatography. Hydrochloride salts are prepared by treatment of the corresponding free base with HCI either in gas phase or 4M dioxane solution, or any other standard method. The synthesis of various corresponding amines is described in Scheme 2,
3, 4 and 5. The synthesis of 3-(2-amino-2-methylpropyl)quinoline illustrates the general procedure to obtain these amines, and it is described in Scheme 2. The reduction of the oxime obtained from 3-quinolinecarboxaldehyde leads to the corresponding benzylic amine. Reaction of the aforementioned amine with 2,4,6- triphenylpyrylium tetrafluoroborate followed by nucleophilic displacement of the
17 pyridinium salt thus formed with the anion of 2-nitropropane, leads to the formation of the corresponding nitro compound which, after reduction, leads to the title compound.
The synthesis of 2-(4-amino-4-methylpentyl)pyridine illustrates the general procedure to obtain pentyl amines, and it is described in Scheme 3. The Curtius rearrangement of 2,2-dimethyl-4-pentenoic acid leads to the corresponding Cbz protected amine. Addition of 9-BBN to the terminal olefin of the protected amine leads to the corresponding boronate. Palladium catalyzed coupling reaction between the boronate and the corresponding aryl bromide (2-bromopyridine in Scheme 3) leads to the formation of the corresponding amine after the removal of the protecting group.
The synthesis of 5-(2-amino-2-methylpropyl)-2,3-dihydrobenzo[b]furan illustrates the general procedure to obtain these amines, and it is described in Scheme 4. Wittig reaction between 2,3-dihydrobenzo[b]furan-5-carboxaldehyde and the anion formed from isopropyltriphenylphosphonium leads to the corresponding olefin. Ritter reaction on the olefin followed by hydrolysis leads to the corresponding amine.
Nuclear magnetic resonance spectra were recorded at either 250 or 400 MHz using, respectively, a Bruker AM 250 or Bruker AC 400 spectrometer. CDCI3 is deuteriochloroform, DMSO-d6 is hexadeuteriodimethylsulfoxide, and CD3OD is tetradeuteriomethanol. Chemical shifts are reported in parts per million (•) downfield from the internal standard tetramethylsilane. Abbreviations for NMR data are as follows: s=singlet, d=doublet, t=triplet, q=quartet, m=multiplet, dd=doublet of doublets, dt=doublet of triplets, app=apparent, br=broad. J indicates the NMR coupling constant measured in Hertz. Continuous wave infrared (IR) spectra were recorded on a Perkin-Elmer 683 infrared spectrometer, and Fourier transform infrared (FTTR) spectra were recorded on a Nicolet Impact 400 D infrared spectrometer. IR and FTIR spectra were recorded in transmission mode, and band positions are reported in inverse wavenumbers (cm"l). Mass spectra were taken on either VG 70 FE, PE Syx API III, or VG ZAB HF instruments, using fast atom bombardment (FAB) or electrospray (ES) ionization techniques. LC/MS/MS was obtained on a Perkin Elmer Sciex API 365 Instrument. Elemental analyses were obtained using a Perkin-Elmer 240C elemental analyzer. Melting
18 points were taken on a Thomas-Hoover melting point apparatus and are uncorrected. All temperatures are reported in degrees Celsius.
Analtech Silica Gel GF and E. Merck Silica Gel 60 F-254 thin layer plates were used for thin layer chromatography. Both flash and gravity chromatography were carried out on E. Merck Kieselgel 60 (230-400 mesh) silica gel. Analytical and preparative HPLC were carried out on Rainin or Beckman chromatographs. ODS refers to an octadecylsilyl derivatized silica gel chromatographic support. 5 μ Apex-ODS indicates an octadecylsilyl derivatized silica gel chromatographic support having a nominal particle size of 5 μ, made by Jones Chromatography, Littleton, Colorado. YMC ODS-AQ® is an ODS chromatographic support and is a registered trademark of YMC Co. Ltd., Kyoto, Japan. PRP-1® is a polymeric (styrene-divinylbenzene) chromatographic support, and is a registered trademark of Hamilton Co., Reno, Nevada) Celite® is a filter aid composed of acid-washed diatomaceous silica, and is a registered trademark of Manville Corp., Denver, Colorado.
All reagents and solvents were obtained from commercial vendors. Starting materials (e.g., amines and epoxides) were synthesized using standard techniques and procedures.
With appropriate manipulation and protection of any chemical functionality, synthesis of the remaining compounds of Formula (I) is accomplished by methods analogous to those above and to those described in the Experimental section.
In order to use a compound of Formula (I) or a pharmaceutically acceptable salt thereof for the treatment of humans and other mammals, it is normally formulated in accordance with standard pharmaceutical practice as a pharmaceutical composition.
The calcilytic compounds can be administered by different routes including intravenous, intraperitoneal, subcutaneous, intramuscular, oral, topical (transdermal), or transmucosal administration. For systemic administration, oral administration is preferred. For oral administration, for example, the compounds can be formulated into conventional oral dosage forms such as capsules, tablets, and liquid preparations such as syrups, elixirs, and concentrated drops.
19 Alternatively, injection (parenteral administration) may be used, e.g., intramuscular, intravenous, intraperitoneal, and subcutaneous. For injection, the compounds of the invention are formulated in liquid solutions, preferably, in physiologically compatible buffers or solutions, such as saline solution, Hank's solution, or Ringer's solution. In addition, the compounds may be formulated in solid form and redissolved or suspended immediately prior to use. Lyophilized forms can also be produced.
Systemic administration can also be by transmucosal or transdermal means. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art, and include, for example, for transmucosal administration, bile salts and fusidic acid derivatives. In addition, detergents may be used to facilitate permeation. Transmucosal administration, for example, may be through nasal sprays, rectal suppositories, or vaginal suppositories. For topical administration, the compounds of the invention can be formulated into ointments, salves, gels, or creams, as is generally known in the art.
The amounts of various calcilytic compounds to be administered can be determined by standard procedures taking into account factors such as the compound IC50, EC50, the biological half-life of the compound, the age, size and weight of the patient, and the disease or disorder associated with the patient. The importance of these and other factors to be considered are known to those of ordinary skill in the art.
Amounts administered also depend on the routes of administration and the degree of oral bioavailability. For example, for compounds with low oral bioavailability, relatively higher doses will have to be administered.
Preferably the composition is in unit dosage form. For oral application, for example, a tablet, or capsule may be administered, for nasal application, a metered aerosol dose may be administered, for transdermal application, a topical formulation or patch may be administered and for transmucosal delivery, a buccal patch may be administered. In each case, dosing is such that the patient may administer a single dose.
Each dosage unit for oral administration contains suitably from 0.01 to 500 mg/Kg, and preferably from 0.1 to 50 mg/Kg, of a compound of Formula (I) or a
20 pharmaceutically acceptable salt thereof, calculated as the free base. The daily dosage for parenteral, nasal, oral inhalation, transmucosal or transdermal routes contains suitably from 0.01 mg to 100 mg/Kg, of a compound of Formula(I). A topical formulation contains suitably 0.01 to 5.0% of a compound of Formula (I). The active ingredient may be administered, for example, from 1 to 6 times per day, preferably once, sufficient to exhibit the desired activity, as is readily apparent to one skilled in the art.
As used herein, "treatment" of a disease includes, but is not limited to prevention, retardation and prophylaxis of the disease. Diseases and disorders which might be treated or prevented, based upon the affected cells, include bone and mineral-related diseases or disorders; hypoparathyroidism; those of the central nervous system such as seizures, stroke, head trauma, spinal cord injury, hypoxia-induced nerve cell damage, such as occurs in cardiac arrest or neonatal distress, epilepsy, neurodegenerative diseases such as Alzheimer's disease, Huntington's disease and Parkinson's disease, dementia, muscle tension, depression, anxiety, panic disorder, obsessive-compulsive disorder, post-traumatic stress disorder, schizophrenia, neuroleptic malignant syndrome, and Tourette's syndrome; diseases involving excess water reabsorption by the kidney, such as syndrome of inappropriate ADH secretion (SIADH), cirrhosis, congestive heart failure, and nephrosis; hypertension; preventing and/or decreasing renal toxicity from cationic antibiotics (e.g., aminoglycoside antibiotics); gut motility disorders such as diarrhea and spastic colon; GI ulcer diseases; GI diseases with excessive calcium absorption such as sarcoidosis; autoimmune diseases and organ transplant rejection; squamous cell carcinoma; and pancreatitis. In a preferred embodiment of the present invention, the present compounds are used to increase serum parathyroid hormone ("PTH") levels. Increasing serum PTH levels can be helpful in treating diseases such as hypoparathyroidism, osteosarcoma, periodontal disease, fracture, osteoarthritis, rheumatoid arthritis, Paget's disease, humoral hypercalcemia malignancy and osteoporosis. Another aspect of the present invention describes a method of treating a patient comprising administering to the patient an amount of a present compound sufficient to increase the serum PTH level. Preferably, the method is carried out by
21 administering an amount of the compound effective to cause an increase in duration and/or quantity of serum PTH level sufficient to have a therapeutic effect.
In various embodiments, the compound administered to a patient causes an increase in serum PTH having a duration of up to one hour, about one to about twenty-four hours, about one to about twelve hours, about one to about six hours, about one to about five hours, about one to about four hours, about two to about five hours, about two to about four hours, or about three to about six hours. In an alternate embodiment of the present invention, the compound administered causes an increase in serum PTH of longer than about twenty-four hours, but the compound is co-administered with an anti-resorptive agent.
In additional different embodiments, the compound administered to a patient causes an increase in serum PTH of up to two fold, two to five fold, five to ten fold, and at least 10 fold, greater than peak serum PTH in the patient. The peak serum level is measured with respect to a patient not undergoing treatment. Composition of Formula (I) and their pharmaceutically acceptable salts, which are active when given orally, can be formulated as syrups, tablets, capsules and lozenges. A syrup formulation will generally consist of a suspension or solution of the compound or salt in a liquid carrier for example, ethanol, peanut oil, olive oil, glycerine or water with a flavoring or coloring agent. Where the composition is in the form of a tablet, any pharmaceutical carrier routinely used for preparing solid formulations may be used. Examples of such carriers include magnesium stearate, terra alba, talc, gelatin, acacia, stearic acid, starch, lactose and sucrose. Where the composition is in the form of a capsule, any routine encapsulation is suitable, for example using the aforementioned carriers in a hard gelatin capsule shell. Where the composition is in the form of a soft gelatin shell capsule any pharmaceutical carrier routinely used for preparing dispersions or suspensions may be considered, for example aqueous gums, celluloses, silicates or oils, and are incorporated in a soft gelatin capsule shell.
Typical parenteral compositions consist of a solution or suspension of a compound or salt in a sterile aqueous or non-aqueous carrier optionally containing a parenterally acceptable oil, for example polyethylene glycol, polyvinylpyrrolidone, lecithin, arachis oil or sesame oil.
22 Typical compositions for inhalation are in the form of a solution, suspension or emulsion that may be administered as a dry powder or in the form of an aerosol using a conventional propellant such as dichlorodifluoromethane or trichlorofluoromethane. A typical suppository formulation comprises a compound of Formula (I) or a pharmaceutically acceptable salt thereof which is active when administered in this way, with a binding and/or lubricating agent, for example polymeric glycols, gelatins, cocoa-butter or other low melting vegetable waxes or fats or their synthetic analogs. Typical dermal and transdermal formulations comprise a conventional aqueous or non-aqueous vehicle, for example a cream, ointment, lotion or paste or are in the form of a medicated plaster, patch or membrane.
Preferably the composition is in unit dosage form, for example a tablet, capsule or metered aerosol dose, so that the patient may administer a single dose. No unacceptable toxological effects are expected when compounds of the present invention are administered in accordance with the present invention.
The biological activity of the compounds of Formula (I) are demonstrated by the following tests: (I) Calcium Receptor Inhibitor Assay Calcilytic activity was measured by determining the IC50 of the test compound for blocking increases of intracellular Ca + elicited by extracellular Ca + in HEK 293 4.0-7 cells stably expressing the human calcium receptor. HEK 293 4.0-7 cells were constructed as described by Rogers et al, J. Bone Miner. Res. 10 Suppl. 1:S483, 1995 (hereby incorporated by reference herein). Intracellular Ca + increases were elicited by increasing extracellular Ca2+ from 1 to 1.75 mM. Intracellular Ca + was measured using fluo-3, a fluorescent calcium indicator. The procedure was as follows:
1. Cells were maintained in T-150 flasks in selection media (DMEM supplemented with 10% fetal bovine serum and 200 ug/mL hygromycin B), under 5% C02:95% air at
37 °C and were grown up to 90% confluency.
2- The medium was decanted and the cell monolayer was washed twice with phosphate-buffered saline (PBS) kept at 37 °C. After the second wash, 6 mL
23 of 0.02 EDTA in PBS was added and incubated for 4 minutes at 37 °C. Following the incubation, cells were dispersed by gentle agitation.
3. Cells from 2 or 3 flasks were pooled and pelleted (100 x g). The cellular pellet was resuspended in 10-15 mL of SPF-PCB+ and pelleted again by centrifugation. This washing was done twice.
Sulfate- and phosphate-free parathyroid cell buffer (SPF-PCB) contains 20 mM Na-Hepes, pH 7.4, 126 mM NaCl, 5 mM KCl, and 1 mM MgCl2. SPF-PCB was made up and stored at 4 °C. On the day of use, SPF-PCB was supplemented with 1 mg/mL of D-glucose and 1 mM CaCl2 and then split into two fractions. To one fraction, bovine serum albumin (BSA; fraction V, ICN) was added at 5 mg/mL (SPF-PCB+). This buffer was used for washing, loading and maintaining the cells. The BSA-free fraction was used for diluting the cells in the cuvette for measurements of fluorescence.
4. The pellet was resuspended in 10 mL of SPF-PCB+ containing 2.2 uM fluo-3 (Molecular Probes) and incubated at room temperature for 35 minutes.
5. Following the incubation period, the cells were pelleted by centrifugation. The resulting pellet was washed with SPF-PCB+. After this washing, cells were resuspended in SPF-PCB+ at a density of 1-2 x 106 cells/mL.
6. For recording fluorescent signals, 300 uL of cell suspension were diluted in 1.2 mL of SPF buffer containing 1 mM CaCl2 and 1 mg/mL of
D-glucose. Measurements of fluorescence were performed at 37 °C with constant stirring using a spectrofluorimeter. Excitation and emission wavelengths were measured at 485 and 535 nm, respectively. To calibrate fluorescence signals, digitonin (5 mg/mL in ethanol) was added to obtain Fmax, and the apparent Fmin was determined by adding Tris-EGTA (2.5 M Tris-Base, 0.3 M EGTA). The concentration of intracellular calcium was calculated using the following equation: Intracellular calcium = (F-Fmin/Fmax) x Kj; where Kfj = 400 nM.
7. To determine the potential calcilytic activity of test compounds, cells were incubated with test compound (or vehicle as a control) for 90 seconds before increasing the concentration of extracellular Ca2+ from 1 to 2mM. Calcilytic compounds were detected by their ability to block, in a concentration-dependent manner, increases in the concentration of intracellular Ca + elicited by extracellular Ca2+ .
24 In general, those compounds having lower IC50 values in the Calcium Receptor Inhibitor Assay are more preferred compounds. Compounds having an IC50 greater than 50 uM were considered to be inactive. Preferred compounds are those having an IC50 of lOuM or lower, more preferred compounds have an IC50 of luM, and most preferred compounds have an IC50 of 0.1 uM or lower. (U) Calcium Receptor Binding Assay
HEK 2934.0-7 cells stably transfected with the Human Parathyroid Calcium Receptor("HuPCaR") were scaled up in T 180 tissue culture flasks. Plasma membrane is obtained by polytron homogenization or glass douncing in buffer (50mM Tris-HCl pH 7.4, ImM EDTA, 3mM MgCl2) in the presence of a protease inhibitor cocktail containing luM Leupeptin, 0.04 uM Pepstatin, and 1 mM PMSF. Aliquoted membrane was snap frozen and stored at -80°C. ^H labeled compound was radiolabeled to a radiospecific activity of 44Ci/mmole and was aliquoted and stored in liquid nitrogen for radiochemical stability. A typical reaction mixture contains 2 nM ^H compound ((R,R)-N-4 -
Methoxy-t-3-3 -methyl- -ethylphenyl-l-(l-naphthyl)ethylamine), or ^H compound (R)-N-[2-Hydroxy-3-(3-chloro-2-cyanophenoxy)propyl]-l,l-dimethyl-2-(4- methoxyphenyl)ethylamine 4-10 ug membrane in homogenization buffer containing 0.1% gelatin and 10% EtOH in a reaction volume of 0.5 mL. Incubation is performed in 12 x 75 polyethylene tubes in an ice water bath. To each tube 25 uL of test sample in 100% EtOH is added, followed by 400 uL of cold incubation buffer, and 25 uL of 40 nM ^H-compound in 100% EtOH for a final concentration of 2nM. The binding reaction is initiated by the addition of 50 uL of 80-200 ug/mL HEK 293 4.0-7 membrane diluted in incubation buffer, and allowed to incubate at 4°C for 30 min. Wash buffer is 50 mM Tris-HCl containing 0.1 % PEL
Nonspecific binding is determined by the addition of 100-fold excess of unlabeled homologous ligand, and is generally 20% of total binding. The binding reaction is terminated by rapid filtration onto 1% PEI pretreated GF/C filters using a Brandel Harvestor. Filters are placed in scintillation fluid and radioactivity assessed by liquid scintillation counting.
The following examples are illustrative, but not limiting of the embodiments of the present invention.
25 Example 1
Preparation of CRVN- r2-Hvdroxy-3-f 3-chloro-2-cyanophenoxy')propyll- 1.1- dimethyl-2-(2.3-dihvdrobenzofb1furan-5yl)ethylamine Hydrochloride 5-(2-Amino-2-methylpropyl)-2.3-dihvdrobenzorb1furan
Sodium hydride (0.89g, 37.1 mmole) was added to 45 mL of DMSO and stirred for 30 min at room temperature. Isopropyltriphenylphosphonium iodide (16.05g, 37.1 mmole) was then added and stirred for 1.5 hours followed by the addition of 2,3-dihydrobenzo[b]furan-5-carboxaldehyde (5.0g, 33.75 mmole). This mixture was stirred for 18 hours at room temperature then poured into water (300 mL) / cone. HCI (5 mL) and extracted with ether. The crude product was chromatographed on silca gel in 1 % MeOH/CHCl3 to afford 5.1 g (87%) of 5-(2- methylpropenyl)-2,3-dihydrobenzo[b]furan , which was 100% pure by GC-MS. To a 0°C suspension of sodium cyanide (1.44g, 29.3 mmole) in 6 mL of acetic acid was slowly added a 0°C solution of sulfuric acid (3.2 mL) in acetic acid (3.2 mL). After stirring for 45 min at 0°C, 5-(2-methylpropenyl)-2,3-d ydrobenzo[b]furan (5.1g, 29.3 mmole) was added, and the mixture allowed to warm to room temperature while stirring for 18 hours. The reaction was poured into ice/ NaOH and extracted with ether. The ether layer was dried over sodium sulfate, then concentrated in vacuo. The crude amidated product was taken up in EtOH/NaOH and refluxed for 24 hours. The ethanol was removed in vacuo, and the residue taken up in ether and water. The ether layer was separated, dried over sodium sulfate and concentrated in vacuo to yield the crude amine as a dark oil. The product was purified by short-path distillation at reduced pressure. (R)-N-[2-Hydroxy-3-(3-chloro-2-cyanophenoxy)propyl]- 1 , 1 -dimethyl-2-(2,3- dihydrobenzo[b]furan-5yl)ethylamine Hydrochloride Using previously described methods, (R)-3-chloro-2-cyanophenyl glycidyl ether (0.398 g, 1.9 mmol) and 5-(2-amino-2-methyIpropyl)-2,3- dihydrobenzo[b]furan (0.382 g, 2.0 mmol) were used to prepare 100 mg of the title compound as a white solid. iH-NMR (CDCI3) • 9.65 (IH, m), 8.13 (IH, m), 7.4
26 (IH, t), 7.05 (2H, d), 6.92 (2H, d), 6.65 (IH, d), 5.7 (IH, d), 4.77 (IH, br m), 4.53 (2H, t), 4.25 (2H, d), 3.4 (2H, m), 3.1 (4H, m), 1.4 (6H, d).
Example 2
Preparation of ("RVN-re-Hvdroxy-S-O-chloro-Σ-cvanophenoxy^ropyπ-l.l- dimethyl-Σ-fquinolin-S-vDethylamine Dihydrochloride 3-(2-Amino-2-methylpropyl')quinoline
To a solution of 3-quinolinecarboxaldehyde (10.27g, 65.3 mmole) in 10 mL of pyridine and 30 mL of ethanol was added methoxylamine hydrochloride (6.0 g, 71.9 mmole). After stirring for 2 hours the solvents were removed under reduced pressure, and the residue taken up in ether and water. The ether layer was separated, dried over sodium sulfate and concentrated in vacuo. The crude oxime (11.91 g, 63.9 mmole) was dissolved in 120 mL of trifluoroacetic acid and treated with zinc powder (13.0 g, 199 mmole). After 10 min, the reaction refluxed spontaneously for a few seconds, and the mixture was stirred for another 3 hours. The mixture was poured into water, and washed with ether. The aqueous layer was then made basic with NaOH, and the amine extracted into ether. The ether layer was separated, dried over sodium sulfate and concentrated in vacuo to yield 8.68 g of 3-(aminomethyl)quinoline. To this amine (8.68 g, 54.9 mmole), dissolved in 200 mL of dichloromethane, was added 2,4,6-triphenylpyrylium tetrafluoroborate (19.56 g, 49.4 mmole), and the reaction stirred at room temperature for 48 hours. The solids were filtered off, and the resulting solution concentrated in vacuo to give 25.4 g (86.3%) of the crude N-(3-quinolinylmethyl)-2,4,6-triphenylpyridinium tetrafluoroborate salt. A solution of this salt (25.4 g, 47.4 mmole) in 100 mL of DMSO was added to the sodium salt of 2-nitropropane (142.1 mmole) (made by adding sodium hydride (3.41 g, 142 mmole) to 50 mL of methanol followed by addition of 2-nitropropane (12.66 g, 142.1 mmole), then removing the methanol in vacuo). The reaction was stirred for 24 hours at 100 C then cooled and diluted with ether and aqueous HCI. The aqueous layer was separated, made basic with NaOH, and extracted with ether. The ether layer was dried over sodium sulfate, and concentrated in vacuo to give after purification on silica gel (in chloroform) 10.7 g
27 (98%) of 3-(2-nitro-2-methylpropyl)quinoline. To this nitro compound (10.7 g, 47.2 mmole) dissolved in 100 mL of trifluoroacetic acid was slowly added zinc powder (9.3 g, 142 mmole). Stirred for 24 hours at room temperature. The reaction mixture was then poured into water and washed with ether. The aqueous layer was separated, made basic with NaOH, and extracted with ether. The ether layer was dried over sodium sulfate, and concentrated in vacuo to give 4.5 g (48%) of 3-(2-amino-2-methylpropyl)quinoline. GC/EI-MS, m/z, (rel. int.) 185 (M* - 15, 3), 143 (58), 115 (11), 58 (100), 42 (7). (R)-N- [2-Hydroxy-3-(3-chloro-2-cyanophenoxy)propyl]- 1 , 1 -dimethy l-2-(quinolin- 3-yl)ethylamine Dihydrochloride
Using previously described methods, (R)-3-chloro-2-cyanophenyl glycidyl ether (0.398g, 1.9 mmol) and 3-(2-amino-2-methylpropyl)quinoline (0.401 g, 2.0 mmol) were used to prepare 130 mg of the title compound as a white solid. ^H- NMR (CDCI3) • 9.7 (IH, br t), 9.25 (IH, s), 9.0 (2H, br s), 8.42 (IH, d), 8.37 (IH, d), 8.1 (IH, dd), 7.93 (IH, dd), 7.65 (IH, dd), 7.35 ( IH, d), 7.28 (IH, d), 4.3 (3H, m), 3.45 (2H, s), 3.3 (2H, m), 2.5 (IH, s), 1.4 (6H, s).
Example 3
Preparation of (R)-N-r2-Hvdroxy-3-(3-chloro-2-cvanophenoxy)propyπ- 1.1- dimethyl-2-(quinolin-2-yl)ethylamine Dihydrochloride 2-f2-Amino-2-methylpropyl)quinoline
Using the method of Example 2, supra, 2-(2-amino-2- methylpropyl)quinoline was prepared from quinoline-2-carboxaldehyde. GC/EI- MS, m/z, (rel. int.) 185 (M+ - 15, 5), 143 (42), 115 (13), 58 (100), 42 (6). (R)-N-[2-Hydroxy-3-(3-chloro-2-cyanophenoxy)propyl]-l,l-dimethyl-2-(quinolin- 2-yl)ethylamine Dihydrochloride Using previously described methods (R)-3-chloro-2-cyanophenyl glycidyl ether (0.2 lg, 1.0 mmol) and 2-(2-amino-2-methylpropyl)quinoline (0.24 g, 1.2 mmol) were used to prepare 24 mg of the title compound as a white solid. 1H-NMR (CDCI3) • 9.7 (IH, m), 9.3 (IH, m), 8.55 (IH, d), 8.39 (IH, d), 7.83 (IH, d), 7.7
28 (2H, m), 7.53 (IH, m), 7.15 (IH, t), 6.75 (2H, m), 4.3 (IH, m), 4.0 (2H, m), 3.65 (2H, dd), 3.15 (2H, m), 1.3 (6H, d).
Example 4
Preparation of (R)-N-r2-Hydroxy-3-(3-chloro-2-cvanophenoxy)propyπ- 1.1- dimethvI-2-(isoquinolin-3-yl1ethylamine Dihydrochloride 3-(2-Amino-2-methylpropyl1isoquinoline
Using the method of Example 2, supra, 3-(2-amino-2- methylpropyl)isoquinoline was prepared from isoquinoline-3-carboxaldehyde. GC EI-MS, m/z, (rel. int.) 185 (M* - 15, 7), 144 (13), 143 (100), 116 (9), 115 (22), 58 (47), 42 (8). (R)-N-[2-Hydroxy-3-(3-chloro-2-cyanophenoxy)propyl]-l,l-dimethyl-2- (isoquinolin-3-yl)ethylamine Dihydrochloride
Using previously described methods (R)-3-chloro-2-cyanophenyl glycidyl ether (0.47g, 2.24 mmol) and 3-(2-amino-2-methylpropyl)isoquinoline (0.49 g, 2.45 mmol) were used to prepare 200 mg of the title compound as a light yellow solid. iH-NMR (CDCI3) • 9.7 (2H, s on top of m), 9.25 (IH, m), 8.45 (IH, d), 8.27 (IH, s), 8.2 (IH, d), 8.1 (IH, t), 7.9 (IH, t), 7.68 (IH, t), 7.35 (IH, d), 7.25 (IH, d), 4.39 (IH, m), 4.3 (2H, s), 3.57 (2H, dd), 3.3 (2H, m), 1.4 (6H, d).
Example 5
Preparation of f R)-N-r2-Hvdroxy-3-(3-chloro-2-cvanophenoxy)propyll- 1.1- dimethyl-4-(2-pyridvI')butylamine Dihydrochloride 4-Benzyloxycarbonylamino-4-methylpent- 1 -ene
The 2,2-dimethyl-4-pentenoic acid (20.7g, 162 mmoles) was dissolved in 300 mL of benzyl alcohol followed by addition of triethylamine (17.98g, 178 mmoles). Diphenyl phosphorylazide (46.67g, 170 mmoles) was added and the reaction heated to 100°C overnight under nitrogen. The product was separated from
29 the excess benzyl alcohol by distillation. The product distilled at approx. 130°C @ 0.01 mm. 9-(4-Benzyloxycarbonylamino-4-methylpentyl)-9-borabicyclo[3.3.1]nonane
To a 0.5 M solution of 9-BBN in THF (100 mL, 50 mmole) was added 4- benzyloxycarbonylamino-4-methylpent-l-ene (11.67 g, 50 mmole). The reaction was allowed to stand for 24 hours at room temperature. Analysis by GC-MS showed no starting alkene left. The solution, which was approximately 0.439 M in the borane, was used without purification. 2-(4-Amino-4-methylpentyl)pyridine To 2-bromopyridine (0.948 g, 6 mmole) was added 9-(4-benzyloxycarbonylamino- 4-methylpentyl)-9-borabicyclo[3.3.1]nonane (12 mL, 5 mmole of a THF solution) in a nitrogen flushed reaction tube. To this solution was added 0.122 g (0.15 mmole) of [ 1 , 1 ' -bis(diphenylphosphino)ferrocene]dichloropalladium(II) dichloromethane complex (1:1), 1.38 g (10 mmole) of potassium carbonate, and 1.25 mL of water. The reaction was stirred for 18 hours at 65 C, then poured into aqueous NaOH, and extracted with ether. The ether layer was separated, washed with brine, dried over sodium sulfate, and concentrated in vacuo. The crude product was taken up in 20 mL of ethanol to which 1 g of palladium hydroxide on carbon (10%) was added. The mixture was stirred for 18 hours under a hydrogen balloon. The reaction mixture was filtered and concentrated in vacuo. The residue was taken up in aqueous HCI, and extracted with ether. The aqueous layer was separated, made basic with NaOH, and extracted with ether. The ether layer was dried over sodium sulfate, and concentrated in vacuo to give 0.63 g of 2-(4-Amino- 4-methylpentyl)pyridine. (R)-N-[2-Hydroxy-3-(3-chloro-2-cyanophenoxy)propyl]-l,l-dimethyl-4-(2- pyridyl)butylamine Dihydrochloride
Using previously described methods (R)-3-chloro-2-cyanophenyl glycidyl ether (0.2 lg, 1.0 mmol) and 2-(4-Amino-4-methylpentyl)pyridine (0.196 g, 1.1 mmol) were used to prepare 19 mg of the title compound as a light yellow solid. LC/MS/MS* (In-Source ISD technique), /z, 388 (M*), 227, 162, 106.
30 Example 6
Preparation of fRVN-r2-Hvdroxy-3-('3-chloro-2-cvano-4- morphoIinosulfonamidophenoxy)propyn-l.l-dimethyl-4-r2-pyridyl)butylamine Dihydrochloride
Using the method of Example 5, supra, (R)-3-chloro-2-cyano-4- moφholinosulfonamidophenyl glycidyl ether (0.3g, 0.83 mmol) and 2-(4-Amino-4- methylpentyl)pyridine (0.156 g, 0.87 mmol) were used to prepare 150 mg of the title compound as an off white solid. iH-NMR (CDCI3) «9.3 (IH, m), 8.8 (2H, d on top of m), 8.55 (IH, t), 8.18 (IH, d), 8.02 (IH, d), 7.95 (IH, dd), 7.5 (IH, d), 4.4 (3H, m), 3.6 (4H, br s), 3.1 (6H, m), 2.5 (2H, s), 1.8 (4H, m), 1.3 (6H, s).
Example 7
Preparation of (R')-N-r2-Hvdroxy-3-(3-chloro-2-cvanophenoxy)propyn-l.l- dimethyl-4-(3-pyridyl")butylamine Dihydrochloride
S-^-Amino^-methylpentvDpyridine
Using the method of Example 5, supra, 0.66 g of 3-(4-Amino-4- methylpentyl)pyridine was prepared, starting with 6 mmoles of 3-bromopyridine.
(R)-N-[2-Hydroxy-3-(3-chloro-2-cyanophenoxy)propyl]- 1 , l-dimethyl-4-(3- pyridyl)butylamine Dihydrochloride Using previously described methods, (R)-3-chloro-2-cyanophenyl glycidyl ether (0.2 lg, 1.0 mmol) and 3-(4-Amino-4-methylpentyl)pyridine (0.196 g, 1.1 mmol) were used to prepare 25 mg of the title compound as a light yellow glassy solid. LC/MS/MS* (In-Source ISD technique), m/z, 388 (M+), 227, 162, 106.
31 Example 8
Preparation of (R)-N-r2-Hvdroxy-3-C3-chloro-2-cvano-4- moφholinosulfonamidophenoxy)propyn- 1.1 -dimethyl-4-(3-pyridyl)butylamine Dihydrochloride
Using the method of Example 5, supra, (R)-3-chloro-2-cyano-4- moφholinosulfonamidophenyl glycidyl ether (0.3g, 0.83 mmol) and 3-(4-Amino-4- methylpentyl)pyridine (0.156 g, 0.87 mmol) were used to prepare 30 mg of the title compound as an off white solid. 1H-NMR (CDCI3) • 9.3 (IH, m), 8.9 (IH, s), 8.8 (2H, d on top of m), 8.56 (IH, d), 8.16 (IH, d), 8.04 (IH, dd), 7.5 (IH, d), 4.4 (3H, m), 3.6 (4H, br s), 3.1 (4H, m), 2.8 (2H, br s), 2.5 (2H, s), 1.7 (4H, m), 1.3 (6H, s).
Example 9
Preparation of ("R)-N-r2-Hydroxy-3-(3-chloro-2-cvanophenoxy)propyll-4- phenylbutylamine Hydrochloride
Using previously described methods, (R)-3-chloro-2-cyanophenyl glycidyl ether (0.2 lg, 1.0 mmol) and 4-phenylbutylamine (0.164 g, 1.1 mmol) were used to prepare 250 mg of the title compound as a white solid. Η NMR (CDC13) d 10.09 (IH, s), 9.38 (IH, s), 9.12 (IH, s), 7.53 (2H, m), 7.19 (7H, m), 6.08 (IH, m), 5.98 IH, m), 4.63 (IH, m), 4.52 (IH, m), 4.23 (3H, m), 3.95 (IH, m), 3.43 (IH, m), 3.20 (IH, m), 3.00 (IH, m), 2.65 (3H, m), 1.86 (2H, m), 1.71 (2H, m).
Example 10
Preparation of ("R -N-r2-Hvdroxy-3-(3-chloro-2-cyanophenoxy)propyll-l.l- dimethyl-4-(2-carbethoxyphenyl)butylamine Hydrochloride Ethyl 2-(4-Amino-4-methylpentyl)benzoate
32 To ethyl 2-bromobenzoate (0.504 g, 2.2 mmole) in a nitrogen flushed reaction tube was added 0.049 g (0.06 mmole) of [1,1'- bis(diphenylphosphino)ferrocene]dichloropalladium(II) dichloromethane complex (1:1) dissolved in 2 mL of DMF. To this solution was added 1.3 g (4 mmoles) of cesium carbonate, followed by 9-(4-benzyloxycarbonylamino-4-methylpentyl)-9- borabicyclo[3.3.1]nonane (4.56 mL, 2.0 mmole of a THF solution). The reaction was stirred for 16.5 hours at 50 C, then poured into aqueous NaOH, and extracted with ether. The ether layer was separated, washed with brine, dried over sodium sulfate, and concentrated in vacuo. The crude product was taken up in 10 mL of ethanol to which 0.3 g of palladium hydroxide on carbon (10%) was added. The mixture was stirred for 18 hours under a hydrogen balloon. The reaction mixture was filtered and concentrated in vacuo. The residue was taken up in aqueous HCI, and extracted with ether. The aqueous layer was separated, made basic with NaOH, and extracted with ether. The ether layer was dried over sodium sulfate, and concentrated in vacuo to give crude ethyl 2-(4-amino-4-methylpentyl)benzoate.
The crude product was purified by reversed-phase HPLC on a C- 18 column using a gradient of 0.1% HCI to 40% acetonitrile in 0.1% HCI. (R)-N-[2-Hydroxy-3-(3-chloro-2-cyanophenoxy)propylJ- 1 , 1 -dimethyl-4-(2- carbethoxyphenyl)butylamine Hydrochloride Using previously described methods, (R)-3-chloro-2-cyanophenyl glycidyl ether (0.2 lg, 1.0 mmol) and l,l-dimethyl-4-(2-carbethoxyphenyl)butylamine (0.274 g, 1.1 mmol) were used to prepare 260 mg of the title compound as a white solid. 'H NMR (CDC13) • 9.54 (IH, s), 8.17 (IH, m), 7.85 (IH, dd), 7.43 (2H, m), 7.24 (2H, m), 7.06 (IH, d), 6.97 (IH, d), 6.00 (IH, d), 4.71 (IH, s), 4.33 (2H, q), 4.26 (2H, d), 3.27 (2H, m), 2.60 (2H, m), 1.85 (2H, m), 1.69 (2H, m), 1.46 (6H, s), 1.37 (3H, t).
Example 11
Preparation of (R)-N-r2-Hvdroxy-3-("3-chloro-2-cvanophenoxy)propyll-l.1- dimethyl-4-(3-carbethoxyphenvDbutylamine Hydrochloride
33 Using previously described methods, (R)-3-chloro-2-cyanophenyl glycidyl ether (0.21g, 1.0 mmol) and l,l-dimethyl-4-(3-carbethoxyphenyl)butylamine (0.274 g, 1.1 mmol) were used to prepare 230 mg of the title compound as a white solid. Η NMR (CDC13) • 9.56 (IH, m), 8.21 (IH, m), 7.86 (2H, m), 7.37 (3H, m), 7.07 (IH, d), 6.94 (IH, d), 5.59 (IH, d), 4.70 (IH, m), 4.35 (2H, q), 4.24 (2H, d), ' 3.25 (2H, m), 2.71 (2H, m), 1.82 (4H, m), 1.49 (6H, s), 1.39 (3H, t).
Example 12
Preparation of R)-N-r2-Hvdroxy-3-(3-chloro-2-cvanophenoxy)propyll- 1.1- dimethyl-4-( -carbethoxyphenyPbutylamine Hydrochloride
Using the method of Example 5, supra, (R)-3-chloro-2-cyanophenyl glycidyl ether (0.2 lg, 1.0 mmol) and l,l-dimethyl-4-(4- carbethoxyphenyl)butylamine (0.274 g, 1.1 mmol) were used to prepare 250 mg of the title compound as a white solid. 'H NMR (CDC13) • 9.56 (IH, m), 8.19 (IH, m), 7.95 (2H, d), 7.43 (IH, ddd), 7.26 (2H, d), 7.07 (IH, d), 6.93 (IH, d), 5.58 (IH, d), 4.69 (IH, m), 4.33 (2H, q), 4.22 (2H, d), 3.23 (2H, m), 2.71 (2H, m), 1.48 (3H, s), 1.47 (3H, s), 1.37 (3H, t).
Example 13
Preparation of CR)-N-r2-Hvdroxy-3-(3-chloro-2-cvanophenoxy)propyll- 1.1- dimethyl-2-('4-ethylpyrid-2-yl')ethylamine Dihydrochloride 1.1 -Dimeth yl-2-(4-ethylpyrid-2- vDethylamine
4 mmoles 5-ethyl-2-methyl pyridine in 4 mL dry ether was treated with 4.32 mmoles of phenyl lithium (1.8 M solution in cyclohexane/ether) at 0°C. After reaction at RT for 1 h the solution was added dropwise to a chilled (ice bath) solution of 2 mmoles isopropylidene-3-nitrobenzene sulfenamide in 2 mL dry ether. After reaction at RT for 1 hr and at reflux for 0.5 hrs the cooled reaction mixture was quenched with 5 mis water. The organic layer was extracted three
34 times with 6 Molar HCI . The pooled HCI extracts were evaporated to an oil, made basic with IO N NaOH and extracted with ether. The ether was extracted twice with pH 7 Phosphate Buffer, buffer extracts made basic with NaOH and extracted with chloroform. Removal of the chloroform resulted in the title compound in 24% yield.
(R)-N-[2-Hydroxy-3-(3-chloro-2-cyanophenoxy)propyl]-l,l-dimethyl-2-(4- ethylpyrid-2-yl)ethylamine Dihydrochloride
Using previously described methods, (R)-3-chloro-2-cyanophenyl glycidyl ether (0.2 lg, 1.0 mmol) and l,l-Dimethyl-2-(4-ethylpyrid-2-yl)ethylamine (0.25 g, 1.4 mmol) were used to prepare 314 mg of the title compound as a white solid. *H- NMR (CDCI3) • 9.95 (IH, br s), 9.05 (IH, br s), 8.62 (lH,s), 8.27 (IH, br s), 8.02 (IH, br s), 7.44 (IH, t), 7.0 (2H, d), 5.6 (2H, br s), 4.7 (IH, m), 4.34 (2H, br s), 3.9 (2H, br s), 3.53 (2H, br s) , 2.86 (2H, q), 1.62 (6H, s), 1.32 (3H, t).
Example 14
(RVN-r2-Hvdroxy-3-(3-chloro-2-cvanophenoxy)propyH-l.l-dimethyl-2- benzamidoethylamine Hydrochloride
Using previously described methods, (R)-3-chloro-2-cyanophenyl glycidyl ether (O.OOg, 00 mmol) and l,l-Dimethyl-2-benzamidoethylamine (00 g, 00 mmol) were used to prepare 000 mg of the title compound as a white solid. H-NMR (CDCL,) • 9.52 (IH, m), 8.40 (IH, m), 8.20 (IH, s) 7.95 (IH, d), 7.36 (4H, m), 7.02 (IH, d), 6.82 (IH, d), 4.70 (IH, m), 4.16 (2H, m), 3.82 (3H, m), 3.37 (2H, m), 1.51 (3H, s), 1.46 (3H, s); 13C NMR (CDC13) -169.2, 161.3, 137.7, 134.7, 133.1, 131.9, 128.5, 127.8, 122.3, 113.8, 110.8, 103.2, 77.2, 70.8, 65.5, 61.4, 46.4, 44.8, 22.0, 21.6.
Example 15 (R)-N-f 2-Hvdroxy-3-(3-chloro-2-cyanophenoxy)propyll- 1.1 -dimethyl-4-phenylbut- 2-vnylamine Hydrochloride
35 Using previously described methods, (R)-3-chloro-2-cyanophenyl glycidyl ether (O.OOg, 00 mmol) and l,l-Dimethyl-4-phenylbut-2-ynylamine (00 g, 00 mmol) were used to prepare 000 mg of the title compound as a white solid. iH- NMR (CDCL,) -9.97 (IH, m), 8.76 (IH, m), 7.41 (IH, ddd), 7.30 (3H, m), 7.18 (2H, m), 7.04 (IH, d), 6.92 (IH, d), 5.63 (IH, m), 4.76 (IH, m), 4.23 (2H, m), 3.51 (2H, m), 1.85 (3H, s), 1.83 (3H, s); 13C NMR (CDC13) • 161.4, 137.8, 135.7, 134.5, 128.2, 127.9, 126.8, 122.2, 113.5, 110.9, 103.4, 86.8, 79.0, 70.9, 65.3, 55.5, 46.8, 26.8, 26.7, 24.7.
Example 16
Preparation of 1. l-dimethyl-2-r(ethyl-4-oxyacetate -phenyllethylamine
A mixture of l-nitro-l,l-dimethyl-2-(4-hydroxyphenyl]ethane (3.9g, 0.02mole), K2C03 (2.76g, 0.02mole) and ethylbromoacetate (3.06g, 0.02mole) were refluxed in 75ml of acetone for 18h. The reaction was cooled to room temperature and filtered. The filtrate was concentrated in vacuo to yield 5.5g of an oil. This oil was dissolved in 75 ml of EtOH and 1 large spatula-full of washed Raney-nickel was added under argon. The mixture was hydrogenated at room temperature and 55 psi for 18 H. The reaction was filtered and the filtrate concentrated in vacuo to an oil which was filtered through a pad of silica gel eluting with 10% MeOH-CH2Cl2 (v/v). The first 200 ml were combined and concentrated in vacuo to yield 3.2g of a pale yellow oil. MS, m/z 252 (M+H), 503 (2M+H).
Formulations for pharmaceutical use incoφorating compounds of the present invention can be prepared in various forms and with numerous excipients. Examples of such formulations are given below.
Example 17 Inhalant Formulation
A compound of Formula (I) (1 mg to 100 mg) is aerosolized from a metered dose inhaler to deliver the desired amount of drug per use.
36 Example 18
Tablet Formulation
Tablets/Ingredients Per Tablet
1. Active ingredient 40 mg
(Cmp. of Formula(I))
2- Corn Starch 20 mg
3. Alginic acid 20 mg
4. Sodium Alginate 20 mg
5. Mg stearate 13 mg
Figure imgf000039_0001
Procedure for tablet formulation
Ingredients 1, 2, 3 and 4 are blended in a suitable mixer/blender. Sufficient water is added portion-wise to the blend with careful mixing after each addition until the mass is of a consistency to permit its conversion to wet granules. The wet mass is converted to granules by passing it through an oscillating granulator using a No. 8 mesh (2.38 mm) screen. The wet granules are then dried in an oven at 140°F (60°C) until dry. The dry granules are lubricated with ingredient No. 5, and the lubricated granules are compressed on a suitable tablet press.
Example 19 Parenteral Formulation
A pharmaceutical composition for parenteral administration is prepared by dissolving an appropriate amount of a compound of Formula (I) in polyethylene glycol with heating. This solution is then diluted with water for injections (to 100 ml). The solution is then rendered sterile by filtration through a 0.22 micron membrane filter and sealed in sterile containers. All publications, including but not limited to patents and patent applications cited in this specification are herein incoφorated by reference as if each individual publication were specifically and individually indicated to be incoφorated by reference as though fully set forth.
37

Claims

What is claimed is:
1. A compound according to Formula (I) hereinbelow:
Y :,X- ^N H,x ^
Formula (I)
wherein:
Yj is a covalent bond, alkylene or alkenylene of up to 4 carbon atoms, unsubstituted or substituted by C╬╝4 alkyl or O;
Y2 is methylene, unsubstituted or substituted by Cj_4 alkyl or haloalkyl; Y3 is covalent bond or selected from the group consisting of O, S, N-R1^ , C1.4 alkylene-O, Cj_4 alkylene-S, and C1.4 alkylene-N-R^ ; F is selected from the group consisting of H, \_4 alkyl, and C3.6 cycloalkyl;
R3 and R4 are, independently, methyl or ethyl, or, together, form cyclopropyl;
R5 is heteroaryl or fused heteroaryl; wherein the hetero-ring contains N, O or S, and is aromatic, dihydro or tetrahydro, unsubstituted or substituted with any substituents being selected from the group consisting of OH, OCH3, CH(CH3)2, halogen, C\.^ alkyl, C . alkoxy, C3.6 cycloalkyl, OS02RIV, CN, N02, OCF3,
CF3, CH2CF3, (CH2)n C02H, (CH2)n C02RIV, and 0-(CH2)n C02RIV; n is an integer from 0 to 3; G is a covalent bond, CHRg or C-Rg ,wherein Rg is H, OH or O (forming a ketone);
R7 is H, OH, or O-C]^ alkyl;
Rg is H or Cj_4 alkyl; or R7 and Rg together form a ketone;
A and B are, independently, selected from the group consisting of a bond, CH2, NH, O, S and C=0, provided that either A or B is selected from CH2 and NH; or A and B together form a bond; or the A-B moiety is represented by CH=CH or CΓëíC;
X is selected from sub formulas (la) to (Ie) hereinbelow:
38
Figure imgf000041_0001
(la)
Figure imgf000041_0002
(lb)
Figure imgf000041_0003
(IC)
Figure imgf000041_0004
(Id)
39
Figure imgf000042_0001
(le)
wherein W is selected from the group consisting of R\, SO2R1, C(0)R╬╣, SO2NR1R1', C(0)NR╬╣R╬╣', C(0)OR╬╣, and SO3R1', wherein Rj and Rj'are independently selected from the group consisting of hydrogen, C}_4 alkyl, C3.6 cycloalkyl, C2.5 alkenyl, C2.5 alkynyl, heterocycloalkyl, aryl and aryl Cj_4 alkyl; or Rj and Rj' together form a 3 to 7 membered optionally substituted heterocyclic ring; wherein any substituents are selected from the group consisting of CN, aryl, CO2R,
CO2NHR, OH, OR, NH2, halo, CF3, OCF3 and NO2; wherein R represents C\_4 alkyl, or C3.6 cycloalkyl;
X\ is selected from the group consisting of CN, NO2, Cl, F, Br, I, H, R', OR', CF3, OCF3 and OSO2R', wherein R' represents Cj.4 alkyl, or C3.6 cycloalkyl; X2 , X3 and X4 are, independently, selected from the group consisting of CN,
N02, Cl, F, Br, I, H, R", OR", CF3, OCF3 and OS02R", provided that either X! or X3 is H, wherein R" is Cj_4 alkyl or haloalkyl; or X\ and X2 together form an aryl or heteroaryl ring, substituted or unsubstituted; wherein the heteroatom is selected from N, S and O; and any substituents are selected from the group consisting of halo, Cj.4 alkyl, OCF3, CF3, OMe, CN, OSO2R' and N02; or X3 and X4 independently represent C(0)Rj; and
R2 is selected from the group consisting of hydrogen, Cj_4 alkyl, C3.6 cycloalkyl, C2.5 alkenyl, C2.5 alkynyl, heterocycloalkyl aryl and aryl-Cj.4 alkyl; Xj" is selected from the group consisting of CN, NO2, Cl, F, Br, I, H, R, OR, CF3, OCF3 and OSO2R, wherein R represents Cj_4 alkyl, or C3.6 cycloalkyl;
X2", X3" and X4" are, independently, selected from the group consisting of CN, N02, Cl, F, Br, I, H, R', OR', CF3, OCF3 and OS02R', provided that either X"! or X'3 is H, wherein R' is C^ alkyl or haloalkyl; or X\" and X2" together form an aryl or heteroaryl ring, substituted or unsubstituted; wherein the heteroatom is
40 selected from N, S and O and any substituents are selected from the group consisting of halo, C╬╝4 alkyl, OCF3, CF3, OMe, CN, OS╬╕2-C1. alkyl, OSO2- C3-6 cycloalkyl and NO2; or X3" and X4" independently represent C(0)Rj; and R\ " and R2" are, independently, selected from the group consisting of hydrogen, Cj.4 alkyl, C3.6 cycloalkyl, C2.5 alkenyl, C2.5 alkynyl, heterocycloalkyl and aryl; or R " and R2" together form a 3 to 7 membered optionally substituted heterocyclic ring; wherein any substituents are selected from the group consisting of CN, aryl, C02R", C02NHR", OH, OR", NH2, halo, CF3, OCF3 and N02; wherein R" represents C1.4 alkyl, or C3.6 cycloalkyl;
X m is selected from the group consisting of CN, NO2, Cl, F, Br, I, H, R, OR, CF3, OCF3 and OSO2R, wherein R represents C1.4 alkyl, or C3.6 cycloalkyl; X2 ", X3"', and X4" are, independently, selected from the group consisting of CN, NO2, Cl, F, Br, I, H, R', OR', CF3, OCF3 and OS0 R', provided that either Xm or X*3 is H, wherein R' is C1.4 alkyl or haloalkyl; or Xj m and X2"' together form an aryl or heteroaryl ring, substituted or unsubstituted; wherein the heteroatom is selected from N, S and O and the substituents are selected from the group consisting of halo, C\^ alkyl, OCF3, CF3, OMe, CN, OS02-Ci_4 alkyl, OS0 -C3_6 cycloalkyl and NO2; or X3*" and X4 m independently represent C(0)R╬╣ ;
R\ " and R2'" are, independently, selected from the group consisting of hydrogen, C╬╣_4 alkyl, C3.6 cycloalkyl, C2.5 alkenyl, C2-5 alkynyl, heterocycloalkyl and aryl; or R╬╣"'and R2"' together form a 3 to 7 membered optionally substituted heterocyclic ring; wherein the substituents are selected from the group consisting of CN, aryl, C02R", C02NHR", OH, OR", NH2, halo, CF3, OCF3 and N02; wherein R" represents Cj_4 alkyl, or C3_g cycloalkyl;
D is selected from the group consisting of H, CN, NO2, Cl, F, Br, I, R, OR, SR, CF3, OCF3 and OSO2R, wherein R represents C╬╣_4 alkyl, C3.6 cycloalkyl, or C╬╣_ 10 aryl or heteroaryl wherein the heteroatom is selected from N, S and O and substituents are selected from the group consisting of halo, Cj_4 alkyl, OCF3, CF3, OMe, CN, OS╬╕2-C!.4 alkyl, OS02- C3-6 cycloalkyl and NO2; n is the integer 1 or 2;
41 each E is independently C or N, provided that no more than two E moieties are N; further provided that when n is 2, each E is C; a and b are optionally present bonds;
Rj w is selected from the group consisting of (CH2)nC╬╕2R', (CH2)nC╬╕2H, (CH2)nCONR'2, (CH2)nCH2OR', OR', SR', CN, N02, Cl, F, Br, I, H, CF3, OCF3, OSO2R', R' and H; wherein R' represents C j.4 alkyl, or C3.6 cycloalkyl; or R\ n is O, forming a ketone such that Y Rj 1V represents -C=0; R2IV is selected from the group consisting of hydrogen, CN, NO2 Cl, F, Br, I, H, R", OR", CF3, OCF3, and OSO2R"; wherein R" represents C^ alkyl, or C3.6 cycloalkyl.
Y is selected from the group consisting of C, CH, O, N and S; provided that when
Y is S, R ,v is O or not present; further provided that when Y is O, R ╬╣v is not present;
X' is selected from the group consisting of CH2, NH, O and S. R9 is selected from the group consisting of O-alkyl, 0-CH2-aryl, and O- aryl; Xi/'" is selected from the group consisting of CN, NO2, Cl, F, Br, I, H, R, OR, CF3, OCF3 and OSO2R, wherein R represents Cj_4 alkyl, or C3.6 cycloalkyl; X2"", X3"", and X4"" are, independently, selected from the group consisting of CN, N02, Cl, F, Br, I, H, R', OR', CF3, OCF3 and OS02R', provided that either X""! or X""3 is H, wherein R' is C 1.4 alkyl or haloalkyl; or X\ "" and X2"" together form an aryl or heteroaryl ring, substituted or unsubstituted; wherein the heteroatom is selected from N, S and O and the substituents are selected from the group consisting of halo, Cj_4 alkyl, OCF3, CF3, OMe, CN, OS02-C2.4 alkyl, OSO2-C3.6 cycloalkyl and N02; or X2"" and X4 "" independently represent C(0)R╬╣ ; and pharmaceutically acceptable salts and complexes thereof.
2. A compound according to claim 1 having a structure according to Formula
(II) hereinbelow::
Figure imgf000044_0001
Formula (II) wherein:
42 R5 is heteroaryl or fused heteroaryl; wherein the hetero-ring contains N, O or S, and is aromatic, dihydro or tetrahydro, unsubstituted or substituted with any substituents being selected from the group consisting of OH, OCH3, CH(CH3)2, halogen, Cj.4 alkyl, C1.4 alkoxy, C3.6 cycloalkyl, OS02RIV, CN, N02, OCF3, CF3, CH2CF3, (CH2)n C02H, (CH2)n C02RIV, and 0-(CH2)n C02RIV; and A and B are, independently, selected from the group consisting of a bond, CH2, NH, O, S and C=0, provided that either A or B is selected from CH2 and NH; or A and B together form a bond; or the A-B moiety is represented by CH=CH or CΓëíC.
3. A compound according to claim 2 wherein: R5 is heteroaryl or fused heteroaryl, wherein the hetero-ring contains N, O or S and is aromatic, dihydro or tetrahydro, unsubstituted or substituted with any substituents being selected from the group consisting of OCH3, halogen, C╬╣_4 alkyl, , CN, N02, OCF3, CF3, and CH2CF3; Rg is H; and A and B are, independently, selected from the group consisting of a bond, CH2, NH, O, S and C=0, provided that either A or B is selected from CH2 and NH, or A and B together form a bond.
4. A compound according to claim 3 wherein:
R5 is heteroaryl or fused heteroaryl, wherein the hetero-ring contains N, O or S and is aromatic, dihydro or tetrahydro, unsubstituted or substituted with any substituents being selected from the group consisting of OCH3, halogen, Cj_4 alkyl, , CN, N02, OCF3, CF3, and CH2CF3;
Rg is H; and
A and B are, independently, selected from the group consisting of a bond, CH2, O, or A and B together form a bond.
5. A compound according to claim 1 selected from the group consisting of: (R)-N-[2-Hydroxy-3-(3-chloro-2-cyanophenoxy)propyl]- 1 , 1 -dimethyl-2-(2,3- dihydrobenzo[b]furan-5yI)ethylamine;
(R)-N- [2-Hydroxy-3-(3-chloro-2-cyanophenoxy)propy 1]- 1 , 1 -dimethyl-2-(quinolin- 3-yl)ethylamine;
(R)-N-[2-Hydroxy-3-(3-chloro-2-cyanophenoxy)propyl]-l,l-dimethyl-2-(quinolin- 2-yl)ethylamine;
43 (R)-N-[2-Hydroxy-3-(3-chloro-2-cyanophenoxy)ρropyl]- 1 , 1 -dimethyl-2-
(isoquinolin-3-yl)ethylamine;
(R)-N-[2-Hydroxy-3-(3-chloro-2-cyanophenoxy)propyl]- 1 , 1 -dimethyl-4-(2- pyridyl)butylamine; (R)-N-[2-Hydroxy-3-(3-chloro-2-cyano-4- moφholinosulfonamidophenoxy)propyl]- 1 , 1 -dimethyl-4-(2-pyridyl)butylamine;
(R)-N-[2-Hydroxy-3-(3-chloro-2-cyanophenoxy)propylJ- 1 , 1 -dimethyl-4-(3- pyridyl)butylamine;
(R)-N-[2-Hydroxy-3-(3-chloro-2-cyano-4- moφholinosulfonaπudophenoxy)propyl]-l,l-dimethyl-4-(3-pyridyl)butylamine;
(R)-N-[2-Hydroxy-3-(3-chloro-2-cyanophenoxy)propyl]- 1 , 1 -dimethyl-4-(4- carbethoxyphenyl)butylamine;
(R)-N-[2-Hydroxy-3-(3-chloro-2-cyanophenoxy)propyl]-l,l-dimethyl-2-(4- ethylpyrid-2-yl)ethylamine; (R)-N- [2-Hydroxy-3-(3-chloro-2-cyanophenoxy )propy 1]- 1 , 1 -dimethyl-2- benzamidoethylamine;
(R)-N-[2-Hydroxy-3-(3-chloro-2-cyanophenoxy)propyl]-4-phenylbutylamine;
(R)-N-[2-Hydroxy-3-(3-chloro-2-cyanophenoxy)propyl]-l,l-dimethyl-4-phenylbut-
2-ynylamine; and pharmaceutically acceptable salts and complexes thereof.
6. A compound according to claim 5 selectedfrom the group consisting of:
(R)-N- [2-Hydroxy-3-(3-chloro-2-cyanophenoxy)propy 1]- 1 , 1 -dimethyl-2-(2,3- dihydrobenzo[b]furan-5yl)ethylamine;
(R)-N-[2-Hydroxy-3-(3-chloro-2-cyanophenoxy)propyl]-l,l-dimethyl-2-(quinolin- 3-yl)ethylamine;
(R)-N-[2-Hydroxy-3-(3-chloro-2-cyanophenoxy)propyl]- 1 , l-dimethyl-2-(quinolin-
2-yl)ethylamine;
(R)-N-[2-Hydroxy-3-(3-chloro-2-cyanophenoxy)propyl]-l,l-dimethyl-2-
(isoquinolin-3-yl)ethylamine; (R)-N-[2-Hydroxy-3-(3-chloro-2-cyanophenoxy)propyl]-l,l-dimethyl-4-(2- pyridyl)butylamine;
(R)-N-[2-Hydroxy-3-(3-chloro-2-cyano-4- moφholinosulfonamidophenoxy)propyl]- 1 , 1 -dimethyl-4-(2-pyridy l)butylamine;
44 (R)-N-[2-Hydroxy-3-(3-chloro-2-cyanophenoxy)propyl]- 1 , l-dimethyl-4-(3- pyridyl)butylamine;
(R)-N-[2-Hydroxy-3-(3-chloro-2-cyano-4- moφholinosulfonamidophenoxy)propyl]- 1 , 1 -dimethyl-4-(3-pyridyl)butylamine; (R)-N- [2-Hydroxy-3-(3-chloro-2-cyanophenoxy)propyl]- 1 , 1 -dimethy l-2-(4- ethylpyrid-2-yl)ethylamine;
(R)-N-[2-Hydroxy-3-(3-chloro-2-cyanophenoxy)propyl]- 1 , 1 -dimethy 1-2- benzamidoethylamine; and
(R)-N-[2-Hydroxy-3-(3-chloro-2-cyanophenoxy)propyl]-4-phenylbutylamine; and pharmaceutically acceptable salts and complexes thereof.
7. A compound according to claim 6 selected from the group consisting of:
(R)-N- [2-Hydroxy-3-(3-chloro-2-cyanophenoxy)propyl]- 1 , 1 -dimethy l-2-(2,3- dihydrobenzo[b]furan-5yl)ethylamine;
(R)-N- [2-Hydroxy-3-(3-chloro-2-cyanophenoxy)propyl]- 1 , 1 -dimethy l-2-(quinolin- 3-yl)ethylamine;
(R)-N- [2-Hydroxy-3-(3-chloro-2-cyanophenoxy)propy 1] -1,1 -dimethyl-2-(quinolin-
2-yl)ethylamine;
(R)-N- [2-Hydroxy-3-(3-chloro-2-cyanophenoxy)propyl]- 1 , 1 -dimethy 1-2-
(isoquinolin-3-yl)ethylamine; (R)-N-[2-Hydroxy-3-(3-chloro-2-cyanophenoxy)propyl]- 1 , 1 -dimethyl-4-(2- pyridyl)butylamine;
(R)-N-[2-Hydroxy-3-(3-chloro-2-cyano-4- moφholinosulfonamidophenoxy)propyl]- 1 , 1 -dimethyl-4-(2-pyridyl)butylamine;
(R)-N- [2-Hydroxy-3-(3-chloro-2-cyanophenoxy)propyl]- 1 , 1 -dimethy l-4-(3- pyridyl)butylamine;
(R)-N-[2-Hydroxy-3-(3-chloro-2-cyano-4- moφholinosulfonamidophenoxy)propyl]-l,l-dimethyl-4-(3-pyridyl)butylamine; and
(R)-N-[2-Hydroxy-3-(3-chloro-2-cyanophenoxy)propyl]-l,l-dimethyl-2-(4- ethylpyrid-2-yl)ethylamine; and pharmaceutically acceptable salts and complexes thereof.
45
8. A pharmaceutical composition for use in treating a disease or disorder characterized by an abnormal bone or mineral homeostasis which comprises a compound according to claim 1 and a pharmaceutically acceptable carrier.
9. A method of antagonizing a calcium receptor which comprises administering to a subject in need thereof an effective amount of a compound according to claim 1.
10. A method of treating a disease or disorder characterized by an abnormal bone or mineral homeostasis which comprises administering to a subject in need of treatment an effective amount of a compound according to claim 1.
11. A method according to claim 10 wherein the bone or mineral disease or disorder is selected from the group consisting of osteosarcoma, periodontal disease, fracture healing, osteoarthritis, rheumatoid arthritis, Paget's disease, humoral hypercalcemia, malignancy and osteoporosis.
12. A method according to claim 11 wherein the bone or mineral disease or disorder is osteoporosis.
13. A method of increasing serum parathyroid levels which comprises administering to a subject in need of treatment an effective amount of a compound according to claim 1.
14. Use of a compound according to claim 1 in the manufacture of a medicament for use in treating a disease or disorder characterized by an abnormal bone or mineral homeostasis.
46
PCT/US1999/007760 1998-04-08 1999-04-08 Calcilytic compounds and method of use WO1999051241A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002327188A CA2327188A1 (en) 1998-04-08 1999-04-08 Calcilytic compounds and method of use
AU35513/99A AU3551399A (en) 1998-04-08 1999-04-08 Calcilytic compounds and method of use
JP2000542012A JP2002510636A (en) 1998-04-08 1999-04-08 Calcilytic compounds and uses
EP99917374A EP1069901A4 (en) 1998-04-08 1999-04-08 Calcilytic compounds and method of use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8108798P 1998-04-08 1998-04-08
US60/081,087 1998-04-08

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US09647794 A-371-Of-International 2000-10-05
US10/005,490 Continuation US20020052509A1 (en) 1998-04-08 2001-12-04 Calcilytic compounds and method of use

Publications (1)

Publication Number Publication Date
WO1999051241A1 true WO1999051241A1 (en) 1999-10-14

Family

ID=22162024

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/007760 WO1999051241A1 (en) 1998-04-08 1999-04-08 Calcilytic compounds and method of use

Country Status (7)

Country Link
EP (1) EP1069901A4 (en)
JP (1) JP2002510636A (en)
AR (1) AR014975A1 (en)
AU (1) AU3551399A (en)
CA (1) CA2327188A1 (en)
CO (1) CO5021223A1 (en)
WO (1) WO1999051241A1 (en)

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001053254A1 (en) * 2000-01-24 2001-07-26 Smithkline Beecham Corporation Calcilytic compounds
EP1200076A1 (en) * 1999-07-31 2002-05-02 SmithKline Beecham Corporation Calcilytic compounds
US6476046B1 (en) 2000-12-04 2002-11-05 Sepracor, Inc. Diazabicyclo[4.3.0]nonanes, and methods of use thereof
EP1308436A1 (en) * 2000-08-11 2003-05-07 Japan Tobacco Inc. Calcium receptor antagonists
EP1368318A2 (en) * 2000-07-21 2003-12-10 SmithKline Beecham Corporation Calcilytic compounds
EP1383511A2 (en) * 2000-10-25 2004-01-28 Smithkline Beecham Corporation Calcilytic compounds
US7053088B2 (en) 2002-05-22 2006-05-30 Amgen Inc. Vanilloid receptor ligands and their use in treatments
US7105537B2 (en) 2003-01-28 2006-09-12 Bristol-Myers Squibb Company 2-substituted cyclic amines as calcium sensing receptor modulators
US7109238B2 (en) 2000-01-24 2006-09-19 Smith Kline Beecham Corporation Calcilytic compounds
US7144888B2 (en) 2002-08-08 2006-12-05 Amgen Inc. Vanilloid receptor ligands and their use in treatments
US7157498B2 (en) 2000-08-08 2007-01-02 Centre National De La Recherche Scientifique (Cnrs) Diamines having a CaSR modulating activity
US7205322B2 (en) 2003-02-12 2007-04-17 Bristol-Myers Squibb Company Thiazolidine compounds as calcium sensing receptor modulators
US7265145B2 (en) 2003-05-28 2007-09-04 Bristol-Myers Squibb Company Substituted piperidines and pyrrolidines as calcium sensing receptor modulators and method
US7285572B2 (en) 2003-05-28 2007-10-23 Japan Tobacco Inc. CaSR antagonist
US7301022B2 (en) 2005-02-15 2007-11-27 Amgen Inc. Vanilloid receptor ligands and their use in treatments
US7304174B2 (en) 2003-04-23 2007-12-04 Japan Tobacco Inc. CaSR antagonist
US7511044B2 (en) 2004-02-11 2009-03-31 Amgen Inc. Vanilloid receptor ligands and their use in treatments
US7514473B2 (en) 2002-11-26 2009-04-07 Smithkline Beecham, Corp. Calcilytic compounds
US7534798B2 (en) 2004-02-11 2009-05-19 Amgen Inc. Vanilloid receptor ligands and their use in treatments
WO2010103429A1 (en) 2009-03-10 2010-09-16 Pfizer Inc. 1,1-(Dimethyl-Ethylamino)-2-Hydroxy-Propoxy]-Ethyl}-3-Methyl-Biphenyl-4- Carboxylic Acid Derivatives As Calcium Receptor Antagonists

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5693310A (en) * 1986-09-26 1997-12-02 Schering Aktiengesellschaft Amide complexes
WO1998045255A1 (en) * 1997-04-08 1998-10-15 Smithkline Beecham Corporation Calcilytic compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5693310A (en) * 1986-09-26 1997-12-02 Schering Aktiengesellschaft Amide complexes
WO1998045255A1 (en) * 1997-04-08 1998-10-15 Smithkline Beecham Corporation Calcilytic compounds

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Chemical Abstracts Service (C A S); 1 January 1998 (1998-01-01), BARMORE R M, ET AL: "PREPARATION OF ARYLALKYLAMINE AS CALCILYTIC COMPOUNDS", XP002945355, Database accession no. 129-302376P *
See also references of EP1069901A4 *

Cited By (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1200076A1 (en) * 1999-07-31 2002-05-02 SmithKline Beecham Corporation Calcilytic compounds
EP1200076A4 (en) * 1999-07-31 2005-02-09 Smithkline Beecham Corp Calcilytic compounds
WO2001053254A1 (en) * 2000-01-24 2001-07-26 Smithkline Beecham Corporation Calcilytic compounds
EP2141146A1 (en) * 2000-01-24 2010-01-06 SmithKline Beecham Corporation Calcilytic compounds
AU764746B2 (en) * 2000-01-24 2003-08-28 Nps Pharmaceuticals, Inc. Calcilytic compounds
US7109238B2 (en) 2000-01-24 2006-09-19 Smith Kline Beecham Corporation Calcilytic compounds
EP1368318A2 (en) * 2000-07-21 2003-12-10 SmithKline Beecham Corporation Calcilytic compounds
EP1368318A4 (en) * 2000-07-21 2006-08-23 Smithkline Beecham Corp Calcilytic compounds
US7157498B2 (en) 2000-08-08 2007-01-02 Centre National De La Recherche Scientifique (Cnrs) Diamines having a CaSR modulating activity
EP1308436A4 (en) * 2000-08-11 2005-10-05 Japan Tobacco Inc Calcium receptor antagonists
US7211685B2 (en) 2000-08-11 2007-05-01 Japan Tobacco Inc. Calcium receptor antagonists
EP1308436A1 (en) * 2000-08-11 2003-05-07 Japan Tobacco Inc. Calcium receptor antagonists
US6916956B2 (en) 2000-08-11 2005-07-12 Japan Tobacco, Inc. Calcium receptor antagonist
EP1383511A4 (en) * 2000-10-25 2005-05-18 Smithkline Beecham Corp Calcilytic compounds
EP1383511A2 (en) * 2000-10-25 2004-01-28 Smithkline Beecham Corporation Calcilytic compounds
US6476046B1 (en) 2000-12-04 2002-11-05 Sepracor, Inc. Diazabicyclo[4.3.0]nonanes, and methods of use thereof
US7053088B2 (en) 2002-05-22 2006-05-30 Amgen Inc. Vanilloid receptor ligands and their use in treatments
US7524874B2 (en) 2002-05-22 2009-04-28 Amgen Inc. Vanilloid receptor ligands and their use in treatments
US7396831B2 (en) 2002-05-22 2008-07-08 Amgen Inc. Vanilloid receptor ligands and their use in treatments
US7332511B2 (en) 2002-08-08 2008-02-19 Amgen Inc. Vanilloid receptor ligands and their use in treatments
US7148221B2 (en) 2002-08-08 2006-12-12 Amgen Inc. Vanilloid receptor ligands and their use in treatments
US7144888B2 (en) 2002-08-08 2006-12-05 Amgen Inc. Vanilloid receptor ligands and their use in treatments
US7514473B2 (en) 2002-11-26 2009-04-07 Smithkline Beecham, Corp. Calcilytic compounds
US9227914B2 (en) 2002-11-26 2016-01-05 GlaxoSmithKline, LLC Calcilytic compounds
US8586631B2 (en) 2002-11-26 2013-11-19 GlaxoSmithKline, LLC Calcilytic compounds
US8399517B2 (en) 2002-11-26 2013-03-19 GlaxoSmithKline, LLC Calcilytic compounds
US7829594B2 (en) 2002-11-26 2010-11-09 GlaxoSmithKline, LLC Calcilytic compounds
US7105537B2 (en) 2003-01-28 2006-09-12 Bristol-Myers Squibb Company 2-substituted cyclic amines as calcium sensing receptor modulators
US7205322B2 (en) 2003-02-12 2007-04-17 Bristol-Myers Squibb Company Thiazolidine compounds as calcium sensing receptor modulators
EP2308828A2 (en) 2003-04-23 2011-04-13 Japan Tobacco Inc. CaSR antagonist
EP2189439A2 (en) 2003-04-23 2010-05-26 Japan Tobacco, Inc. CaSR antagonist
EP2189439A3 (en) * 2003-04-23 2011-05-04 Japan Tobacco, Inc. CaSR antagonist
US7304174B2 (en) 2003-04-23 2007-12-04 Japan Tobacco Inc. CaSR antagonist
EP2308828A3 (en) * 2003-04-23 2013-05-22 Japan Tobacco Inc. CaSR antagonist
US7265145B2 (en) 2003-05-28 2007-09-04 Bristol-Myers Squibb Company Substituted piperidines and pyrrolidines as calcium sensing receptor modulators and method
US7285572B2 (en) 2003-05-28 2007-10-23 Japan Tobacco Inc. CaSR antagonist
US7534798B2 (en) 2004-02-11 2009-05-19 Amgen Inc. Vanilloid receptor ligands and their use in treatments
US7511044B2 (en) 2004-02-11 2009-03-31 Amgen Inc. Vanilloid receptor ligands and their use in treatments
US8227469B2 (en) 2004-02-11 2012-07-24 Amgen Inc. Vanilloid receptor ligands and their use in treatments
US7301022B2 (en) 2005-02-15 2007-11-27 Amgen Inc. Vanilloid receptor ligands and their use in treatments
WO2010103429A1 (en) 2009-03-10 2010-09-16 Pfizer Inc. 1,1-(Dimethyl-Ethylamino)-2-Hydroxy-Propoxy]-Ethyl}-3-Methyl-Biphenyl-4- Carboxylic Acid Derivatives As Calcium Receptor Antagonists

Also Published As

Publication number Publication date
JP2002510636A (en) 2002-04-09
CA2327188A1 (en) 1999-10-14
CO5021223A1 (en) 2001-03-27
EP1069901A1 (en) 2001-01-24
EP1069901A4 (en) 2001-06-13
AU3551399A (en) 1999-10-25
AR014975A1 (en) 2001-04-11

Similar Documents

Publication Publication Date Title
WO1999051241A1 (en) Calcilytic compounds and method of use
US6335338B1 (en) Calcilytic compounds
US6417215B1 (en) Calcilytic compounds
EP1368318B1 (en) Calcilytic compounds
EP1713767A1 (en) Calcilytic compounds
US20040009980A1 (en) Calcilytic compounds
EP1254106B1 (en) Calcilytic compounds
US6864267B2 (en) Calcilytic compounds
AU2001276923A1 (en) Calcilytic compounds
US6291459B1 (en) Calcilytic compounds
EP1383511B1 (en) Calcilytic compounds
US7109238B2 (en) Calcilytic compounds
US20020052509A1 (en) Calcilytic compounds and method of use
WO2005030746A1 (en) Calcilytic compounds

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AU BA BB BG BR CA CN CZ EE GE GH GM HR HU ID IL IN IS JP KP KR LC LK LR LT LV MG MK MN MX NO NZ PL RO SG SI SK SL TR TT UA US UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2327188

Country of ref document: CA

Ref country code: CA

Ref document number: 2327188

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 09647794

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: KR

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 542012

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1999917374

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999917374

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1999917374

Country of ref document: EP